

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2006306491 B2

(54) Title
Piperazine derivatives useful as CCR5 antagonists

(51) International Patent Classification(s)
C07D 401/14 (2006.01) **A61P 37/06** (2006.01)
A61K 31/506 (2006.01) **C07H 17/02** (2006.01)
A61P 31/18 (2006.01)

(21) Application No: **2006306491** (22) Date of Filing: **2006.10.18**

(87) WIPO No: **WO07/050375**

(30) Priority Data

(31) Number **11/255,643** (32) Date **2005.10.21** (33) Country **US**

(43) Publication Date: **2007.05.03**
(44) Accepted Journal Date: **2012.12.13**

(71) Applicant(s)
Merck Sharp & Dohme Corp.

(72) Inventor(s)
Ghosal, Anima;Miller, Michael W.;Alton, Kevin B.;Ramanathan, Ragulan;Chowdhury, Swapan K.

(74) Agent / Attorney
Griffith Hack, Level 29, Northpoint 100 Miller Street, North Sydney, NSW, 2060

(56) Related Art
Tagat, J. R. et al. Journal of Medicinal Chemistry, 2004, vol. 47, pages 2405-2408

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 May 2007 (03.05.2007)

PCT

(10) International Publication Number
WO 2007/050375 A3

(51) International Patent Classification:

C07D 401/14 (2006.01) A61P 31/18 (2006.01)
C07H 17/02 (2006.01) A61P 37/06 (2006.01)
A61K 31/506 (2006.01)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2006/040636

(22) International Filing Date: 18 October 2006 (18.10.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
11/255,643 21 October 2005 (21.10.2005) US

(71) Applicant (for all designated States except US): SCHERRING CORPORATION [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033-0530 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RAMANTHAN, Ragulan [LK/US]; 7 Country Woods Drive, Kendall Park, NJ 08824 (US). GHOSAL, Anima [IN/US]; 5005 Hana Road, Edison, NJ 08817 (US). MILLER, Michael, W. [US/US]; 1862 Lamberts Mill Road, Scotch Plains, NJ 07076 (US). CHOWDHURY, Swapan, K. [US/US]; 7 Sunny Slope Drive, Warren, NJ 07059 (US). ALTON, Kevin, B. [US/US]; 70 Summit Avenue, Cedar Knolls, NJ 07927 (US).

(74) Agent: BANERJEE, Krishna, G.; Schering-plough Corporation, 2000 Galloping Hill Road, Patent Dept. K-6-1990, Kenilworth, New Jersey 07033-0530 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))


Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
14 June 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS



(57) Abstract: CCR5 antagonists having the following core structure Formula (I) (AA) are claimed, for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis .

WO 2007/050375 A3

PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

BACKGROUND

The present disclosure relates to piperazine derivatives useful as 5 selective CCR5 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds. The disclosure also relates to the use of a combination of a CCR5 antagonist of this disclosure and one or more antiviral or other agents useful in the treatment of Human 10 Immunodeficiency Virus (HIV). The disclosure further relates to the use of a CCR-5 antagonist of this disclosure, alone or in combination with another agent, in the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis.

The global health crisis caused by HIV, the causative agent of Acquired 15 Immunodeficiency Syndrome (AIDS), is unquestioned, and while recent advances in drug therapies have been successful in slowing the progression of AIDS, there is still a need to find a safer, more efficient, less expensive way to control the virus.

It has been reported that the CCR5 gene plays a role in resistance to 20 HIV infection. HIV infection begins by attachment of the virus to a target cell membrane through interaction with the cellular receptor CD4 and a secondary chemokine co-receptor molecule, and proceeds by replication and dissemination of infected cells through the blood and other tissue. There are various chemokine receptors, but for macrophage-tropic HIV, believed to be the 25 key pathogenic strain that replicates *in vivo* in the early stages of infection, the principal chemokine receptor required for the entry of HIV into the cell is CCR5. Therefore, interfering with the interaction between the viral receptor CCR5 and HIV can block HIV entry into the cell. The present disclosure relates to small molecules which are CCR5 antagonists.

CCR-5 receptors have been reported to mediate cell transfer in 30 inflammatory diseases such as arthritis, rheumatoid arthritis, atopic dermatitis, psoriasis, asthma and allergies, and inhibitors of such receptors are expected to be useful in the treatment of such diseases, and in the treatment of other inflammatory diseases or conditions such as inflammatory bowel disease, 35 multiple sclerosis, solid organ transplant rejection and graft v. host disease.

- 2 -

Related piperazine derivatives which are muscarinic antagonists useful in the treatment of cognitive disorders such as Alzheimer's disease are disclosed in US patents 5,883,096; 6,037,352; 5,889,006.


5 A-M. Vandamme et al., Antiviral Chemistry & Chemotherapy, 9:187-203 (1998) disclose current clinical treatments of HIV-1 infections in man including at least triple drug combinations or so-called Highly Active Antiretroviral Therapy ("HAART"); HAART involves various combinations of nucleoside reverse transcriptase inhibitors ("NRTI"), non-nucleoside reverse transcriptase inhibitors ("NNRTI") and HIV protease inhibitors ("PI"). In compliant drug-naive 10 patients, HAART is effective in reducing mortality and progression of HIV-1 to AIDS. However, these multidrug therapies do not eliminate HIV-1 and long-term treatment usually results in multidrug resistance. Development of new drug therapies to provide better HIV-1 treatment remains a priority.

15 Summary Of the invention

The present invention provides the following [1] to [13]:

[1] A compound in pure and isolated form, said compound is:

20



or a pharmaceutically acceptable salt or solvate thereof.

[2] A pharmaceutical composition comprising a compound of item [1] or a 25 pharmaceutically acceptable salt or solvate thereof in combination with a pharmaceutically acceptable carrier.

[3] A method of treating Human Immunodeficiency Virus comprising 30 administering to a human in need of such treatment a therapeutically effective amount of the compound of item [1] or a pharmaceutically acceptable salt or solvate thereof.

[4] The method of item [3] further comprising administering one or more antiviral or other agents useful in the treatment of Human Immuno-deficiency Virus in combination with the compound of item [1] or a pharmaceutically acceptable salt or solvate thereof.

5 [5] The method of item [4] wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

[6] The method of item [5] wherein the antiviral agent is selected from the group consisting of zidovudine, lamivudine, zalcitabine, didanosine, stavudine, 10 abacavir, adefovir dipivoxil, lobucavir, BCH-10652, emtricitabine, beta-L-FD4, DAPD, idenosine, nevirapine, delavirdine, efavirenz, PNU-142721, AG-1549, MKC-442, (+)-calanolide A and B, saquinavir, indinavir, ritonavir, nelfinavir, lasinavir, DMP-450, BMS-2322623, ABT-378, amprenavir, hydroxyurea, ribavirin, IL-2, IL-12, penta fuside, Yissum No. 11607 and AG-1549.

15 [7] A method treating solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, comprising administering to a human in need of such treatment a therapeutically effective amount of the compound of item [1] or a pharmaceutically acceptable salt or solvate thereof.


20 [8] The method of item [8] for the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, further comprising one or more other agents useful in the treatment of said diseases.

25 [9] A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat Human Immunodeficiency Virus which comprises in one container a pharmaceutical composition comprising an effective amount of the compound of item [1] or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier, and in separate containers, one or more pharmaceutical composition comprising an effective amount of a antiviral or other agent useful 30

- 2b -

in the treatment of Human Immunodeficiency Virus in a pharmaceutically acceptable carrier.

[10] A method of determining if a patient has been administered the compound of the formula



5

the method comprising the step of determining if a plasma, urine, bile or fecal sample obtained from the patient shows the presence of a compound of item [1].


[11] Use of a compound of item [1] or a pharmaceutically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of Human Immunodeficiency Virus.

[12] Use of a compound of item [1] or a pharmaceutically acceptable salt, solvate or ester thereof for the preparation of a medicament for the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis psoriasis, asthma, allergies or multiple sclerosis.

Also disclosed herein is the treatment of HIV comprising administering to a mammal in need of such treatment an effective amount of a CCR5 antagonist represented by the structural formula I:

- 2c -

5




or a pharmaceutically acceptable salt thereof, wherein

10 R is R⁸-phenyl, R⁸-pyridyl, R⁸-thiophenyl or R⁸-naphthyl;

R^1 is hydrogen or C_1 - C_6 alkyl;

R^2 is R^9 , R^{10} , R^{11} -phenyl; R^9 , R^{10} , R^{11} -substituted 6-membered heteroaryl; R^9 , R^{10} , R^{11} -substituted 6-membered heteroaryl N-oxide;

R^{12} , R^{13} -substituted 5-membered heteroaryl; naphthyl; fluorenly; diphenylmethyl





R^3 is hydrogen, C_1 - C_6 alkyl, $(C_1$ - $C_6)$ alkoxy(C_1 - C_6)alkyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl(C_1 - C_6)alkyl, R^8 -phenyl, R^8 -phenyl(C_1 - C_6)alkyl, R^8 -naphthyl, R^8 -naphthyl(C_1 - C_6)alkyl, R^8 -heteroaryl or R^8 -heteroaryl(C_1 - C_6)alkyl;

R^4 , R^5 , R^7 and R^{13} are independently selected from the group consisting of hydrogen and $(C_1$ - $C_6)$ -alkyl;

R⁶ is hydrogen, C₁-C₆ alkyl or C₂-C₆ alkenyl;

R⁸ is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₁-C₆ alkoxy, -CF₃, CF₃O-, CH₃C(O)-, -CN, CH₃SO₂-, CF₃SO₂-, R¹⁴-phenyl, R¹⁴-benzyl, CH₃C(=NOCH₃),

5 CH₃C(=NOCH₂CH₃), , -NH₂, -NHCOCF₃, -NHCONH(C₁-C₆ alkyl), -NHCO(C₁-C₆ alkyl), -NHSO₂(C₁-C₆ alkyl),

5-membered heteroaryl and , wherein X is -O-, -NH- or -N(CH₃)-;

R⁹ and R¹⁰ are independently selected from the group consisting of (C₁-C₆)alkyl, halogen, -NR¹⁷R¹⁸, -OH, -CF₃, -OCH₃, -O-acyl, -OCF₃ and

10 -Si(CH₃)₃;

R¹¹ is R⁹, hydrogen, phenyl, -NO₂, -CN, -CH₂F, -CHF₂, -CHO, -CH=NOR¹⁷, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, -N(R¹⁷)CONR¹⁸R¹⁹, -NHCONH(chloro-(C₁-C₆)alkyl), -NHCONH((C₃-C₁)cycloalkyl(C₁-C₆)alkyl), -NHCO(C₁-C₆)alkyl, -NHCOCF₃, -NHSO₂N((C₁-C₆)alkyl)₂, -NHSO₂(C₁-C₆)alkyl, -N(SO₂CF₃)₂, -NHCO₂(C₁-C₆)alkyl, C₃-C₁₀ cycloalkyl, -SR²⁰, -SOR²⁰, -SO₂R²⁰, -SO₂NH(C₁-C₆ alkyl), -OSO₂(C₁-C₆)alkyl, -OSO₂CF₃, hydroxy(C₁-C₆)alkyl, -CON R¹⁷R¹⁸, -CON(CH₂CH₂-O-CH₃)₂, -OCONH(C₁-C₆)alkyl, -CO₂R¹⁷, -Si(CH₃)₃ or -B(OC(CH₃)₂)₂;

R¹² is (C₁-C₆)alkyl, -NH₂ or R¹⁴-phenyl;

20 R¹⁴ is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl, -CF₃, -CO₂R₁₇, -CN, (C₁-C₆)alkoxy and halogen;

R¹⁵ and R¹⁶ are independently selected from the group consisting of hydrogen and C₁-C₆ alkyl, or R¹⁵ and R¹⁶ together are a C₂-C₅ alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;


25 R¹⁷, R¹⁸ and R¹⁹ are independently selected from the group consisting of H and C₁-C₆ alkyl; and

R²⁰ is C₁-C₆ alkyl or phenyl.


30 Preferred are compounds of formula I wherein R is R⁸-phenyl or R⁸-naphthyl, especially wherein R⁸ is a single substituent, and especially wherein the R⁸ substituent is in the 4-position. For R⁸-phenyl, preferred R⁸ substituents are -CF₃, -OCF₃, CH₃SO₂-, CH₃CO-, CH₃C(=NOCH₃)-, Br and I. For R⁸-naphthyl, R⁸ is preferably C₁-C₆ alkoxy. Also preferred are compounds of formula I wherein R³ is hydrogen, (C₁-C₆) alkyl, R⁸-phenyl, R⁸-benzyl or R⁸-pyridyl; more preferred

definitions for R^3 are methyl, ethyl, phenyl, benzyl and pyridyl. R^1 is preferably hydrogen. For compounds of formula I, R^6 is preferably hydrogen or methyl, especially methyl. R^4 is preferably methyl; R^5 and R^7 are each preferably hydrogen.


5 In compounds of formula I, R^2 is preferably R^9 , R^{10} , R^{11} -phenyl, R^9 , R^{10} , R^{11} -pyridyl or an N-oxide thereof, or R^9 , R^{10} , R^{11} -pyrimidyl. When R^2 is pyridyl, it is preferably 3- or 4-pyridyl, and when pyrimidyl, it is preferably 5-pyrimidyl. The R^9 and R^{10} substituents are preferably attached to carbon ring members adjacent to the carbon joining the ring to the rest of the molecule and the R^{11} substituent can be attached to any of the remaining unsubstituted carbon ring members, for example as shown in the following structures:



15 Preferred R^9 and R^{10} substituents are: (C_1 - C_6)alkyl, especially methyl; halogen, especially chloro or bromo, -OH and -NH₂. When R^2 is phenyl, R^{11} is preferably hydrogen or -OH; when R^2 is pyridyl, R^{11} is preferably hydrogen; and when R^2 is pyrimidyl, R^{11} is preferably hydrogen, methyl or phenyl. Examples of particularly preferred R^2 groups are as follows:




20 Also disclosed are novel CCR5 antagonist compounds represented by the structural formula II



or a pharmaceutically acceptable salt thereof, wherein

(1) R^a is R^{8a} -phenyl, R^{8b} -pyridyl, R^{8b} -thiophenyl or R^8 -naphthyl;
 R^1 is hydrogen or C_1 - C_6 alkyl;

5 R^2 is R^9 , R^{10} , R^{11} -phenyl; R^9 , R^{10} , R^{11} -substituted 6-membered heteroaryl; R^9 , R^{10} , R^{11} -substituted 6-membered heteroaryl N-oxide; R^{12} , R^{13} -substituted 5-membered heteroaryl; naphthyl; fluorenlyl;





10 R^3 is hydrogen, C_1 - C_6 alkyl, $(C_1$ - $C_6)$ alkoxy(C_1 - C_6)alkyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkyl(C_1 - C_6)alkyl, R^8 -phenyl, R^8 -phenyl(C_1 - C_6)alkyl, R^8 -naphthyl, R^8 -naphthyl(C_1 - C_6)alkyl, R^8 -heteroaryl or R^8 -heteroaryl(C_1 - C_6)alkyl;

R^4 , R^5 , R^7 and R^{13} are independently selected from the group consisting of hydrogen and (C_1 - C_6)-alkyl;


R^6 is hydrogen, C_1 - C_6 alkyl or C_2 - C_6 alkenyl;

15 R^8 is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, $-CF_3$, CF_3O -, $CH_3C(O)$ -, $-CN$, CH_3SO_2 -, CF_3SO_2 -, R^{14} -phenyl, R^{14} -benzyl, $CH_3C(=NOCH_3)$,


$CH_3C(=NOCH_2CH_3)$, , $-NH_2$, $-NHCOCF_3$, $-NHCONH(C_1$ - C_6 alkyl), $-NHCO(C_1$ - C_6 alkyl), $-NHSO_2(C_1$ - C_6 alkyl),


20 5-membered heteroaryl and , wherein X is $-O$ -, $-NH$ - or $-N(CH_3)$;

R^{8a} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, $-CF_3$, CF_3O -, $-CN$, CF_3SO_2 -, R^{14} -phenyl, $-NHCOCF_3$, 5-

membered heteroaryl and , wherein X is as defined above;

25 R^{8b} is 1 to 3 substituents independently selected from the group consisting of hydrogen, halogen, $-CF_3$, CF_3O -, $CH_3C(O)$ -, $-CN$, CF_3SO_2 -, R^{14} -benzyl,

$CH_3C(=NOCH_3)$, $CH_3C(=NOCH_2CH_3)$, ,



-NHCOCF₃, 5-membered heteroaryl and $\text{--N}(\text{C}_1\text{--C}_6\text{alkyl})\text{C}(=\text{O})\text{X}$, wherein X is as defined above; R⁹ and R¹⁰ are independently selected from the group consisting of (C₁-C₆)alkyl, halogen, -NR¹⁷R¹⁸, -OH, -CF₃, -OCH₃, -O-acyl, -OCF₃ and -Si(CH₃)₃;

5 R¹¹ is R⁹, hydrogen, phenyl, -NO₂, -CN, -CH₂F, -CHF₂, -CHO, -CH=NOR¹⁷, pyridyl, pyridyl N-oxide, pyrimidinyl, pyrazinyl, -N(R¹⁷)CONR¹⁸R¹⁹, -NHCONH(chloro-(C₁-C₆)alkyl), -NHCONH((C₃-C₁)cycloalkyl(C₁-C₆)alkyl), -NHCO(C₁-C₆)alkyl, -NHCOCF₃, -NHSO₂N((C₁-C₆)alkyl)₂, -NHSO₂(C₁-C₆)alkyl, -N(SO₂CF₃)₂, -NHCO₂(C₁-C₆)alkyl, C₃-C₁₀ 10 cycloalkyl, -SR²⁰, -SOR²⁰, -SO₂R²⁰, -SO₂NH(C₁-C₆ alkyl), -OSO₂(C₁-C₆)alkyl, -OSO₂CF₃, hydroxy(C₁-C₆)alkyl, -CON R¹⁷R¹⁸, -CON(CH₂CH₂-O-CH₃)₂, -OCONH(C₁-C₆)alkyl, -CO₂R¹⁷, -Si(CH₃)₃ or -B(OC(CH₃)₂)₂; R¹² is (C₁-C₆)alkyl, -NH₂ or R¹⁴-phenyl;


15 R¹⁴ is 1 to 3 substituents independently selected from the group consisting of hydrogen, (C₁-C₆) alkyl, -CF₃, -CO₂R₁₇, -CN, (C₁-C₆)alkoxy and halogen;

R¹⁵ and R¹⁶ are independently selected from the group consisting of hydrogen and C₁-C₆ alkyl, or R¹⁵ and R¹⁶ together are a C₂-C₅ alkylene group and with the carbon to which they are attached form a spiro ring of 3 to 6 carbon atoms;

20 R¹⁷, R¹⁸ and R¹⁹ are independently selected from the group consisting of H and C₁-C₆ alkyl; and

R²⁰ is C₁-C₆ alkyl or phenyl; or

(2) R^a is R⁸-phenyl, R⁸-pyridyl or R⁸-thiophenyl;



R² is fluorenyl, diphenylmethyl, or

25 and R¹, R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹ and R²⁰ are as defined in (1).

Preferred compounds of formula II are those defined in (1).

More preferred are those of formula II(1) wherein R^a is R^{8a}-phenyl or R⁸-naphthyl, wherein R^{8a} is -CF₃, CF₃O- or halogen and R⁸ is C₁-C₆ alkoxy. The R^{8a} or R⁸ substituent is preferably a single substituent; it is especially preferred that the R^{8a} or R⁸ substituent is in the 4-position. Also preferred are compounds of formula II(1) wherein R³ is hydrogen, (C₁-C₆) alkyl, R⁸-phenyl, R⁸-benzyl or R⁸-pyridyl; more preferred definitions for R³ are methyl, ethyl, phenyl, benzyl and

pyridyl. R¹ is preferably hydrogen. For compounds of formula II(1), R⁶ is preferably hydrogen or methyl, especially methyl. R⁴ is preferably methyl; R⁵ and R⁷ are each preferably hydrogen.

5 R² in formula II(1) is preferably as defined for formula I, i.e., R⁹, R¹⁰, R¹¹-phenyl, R⁹, R¹⁰, R¹¹-pyridyl or an N-oxide thereof, or R⁹, R¹⁰, R¹¹-pyrimidyl, wherein the R⁹, R¹⁰, R¹¹-substitution is as defined above for preferred compounds of formula I.

10 Also disclosed herein is a pharmaceutical composition for treatment of HIV comprising an effective amount of a CCR5 antagonist of formula II in combination with a pharmaceutically acceptable carrier. Also disclosed herein is a pharmaceutical composition for treatment of solid organ transplant rejection, graft v. host disease, 15 arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis comprising an effective amount of a CCR5 antagonist of formula II in combination with a pharmaceutically acceptable carrier.

20 Also disclosed herein is a method of treatment of HIV comprising administering to a human in need of such treatment an effective amount of a CCR5 antagonist compound of formula II. Also disclosed herein is a method of treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis comprising administering to a human in need of such treatment an effective amount of 25 a CCR5 antagonist compound of formula I or II.

30 Also disclosed herein is the use of a CCR5 antagonist of formula I or II of this invention in combination with one or more antiviral or other agents useful in the treatment of Human Immunodeficiency Virus for the treatment of AIDS. Also disclosed herein is the use of a CCR5 antagonist of formula I or II of this invention in combination with one or more other agents useful in the treatment of solid organ transplant rejection, graft v. host disease, inflammatory bowel disease, rheumatoid arthritis or multiple sclerosis. The CCR5 and antiviral or other agents which are components of the combination can be administered in a single dosage form or they can be administered separately; a kit comprising separate dosage forms of the actives is also contemplated.

DESCRIPTION OF DRAWINGS

Figure 1 shows biotransformation of Vicriviroc in human, monkey and rat following a single oral dose of ¹⁴C-VIC.

Figure 2 shows comparison of representative radiochromatographic profiles of pooled plasma extract following a single oral administration of Vicriviroc to healthy male volunteers, male monkeys and rats

5 Figure 3 shows comparison of representative radiochromatographic profiles of pooled urine following a single oral administration of Vicriviroc to healthy male volunteers, male monkeys and rats.

Figure 4 shows comparison of representative radiochromatographic profiles of pooled fecal extract following a single oral administration of Vicriviroc to healthy male volunteers, male monkeys and rats.

10

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following terms are used as defined below unless otherwise indicated.

15 Alkyl represents straight and branched carbon chains and contains from one to six carbon atoms.

Alkenyl represents C₂-C₆ carbon chains having one or two unsaturated bonds, provided that two unsaturated bonds are not adjacent to each other.

Substituted phenyl means that the phenyl group can be substituted at any available position on the phenyl ring.

20 Acyl means a radical of a carboxylic acid having the formula alkyl-C(O)-, aryl-C(O)-, aralkyl-C(O)-, (C₃-C₇)cycloalkyl-C(O)-, (C₃-C₇)cycloalkyl-(C₁-C₆)alkyl-C(O)-, and heteroaryl-C(O)-, wherein alkyl and heteroaryl are as defined herein; aryl is R¹⁴-phenyl or R¹⁴-naphthyl; and aralkyl is aryl-(C₁-C₆)alkyl, wherein aryl is as defined above.

25 Heteroaryl represents cyclic aromatic groups of 5 or 6 atoms or bicyclic groups of 11 to 12 atoms having 1 or 2 heteroatoms independently selected from O, S or N, said heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, provided that the rings do not contain adjacent oxygen and/or sulfur atoms. For 30 6-membered heteroaryl rings, carbon atoms can be substituted by R⁹, R¹⁰ or R¹¹ groups. Nitrogen atoms can form an N-oxide. All regioisomers are contemplated, e.g., 2-pyridyl, 3-pyridyl and 4-pyridyl. Typical 6-membered heteroaryl groups are pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl and the N-oxides thereof. For 5-membered heteroaryl rings, carbon atoms can be substituted by 35 R¹² or R¹³ groups. Typical 5-membered heteroaryl rings are furyl, thienyl, pyrrolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl and isoxazolyl.

5-Membered rings having one heteroatom can be joined through the 2- or 3-position; 5-membered rings having two heteroatoms are preferably joined through the 4-position. Bicyclic groups typically are benzo-fused ring systems derived from the heteroaryl groups named above, e.g. quinolyl, phthalazinyl, quinazolinyl, benzofuranyl, benzothienyl and indolyl.

Preferred points of substitution for 6-membered heteroaryl rings at R² are described above. When R² is a 5-membered heteroaryl group, the R¹² and R¹³ substituents are preferably attached to carbon ring members adjacent to the carbon joining the ring to the rest of the molecule, and R¹² is preferably alkyl; however, if a heteroatom is adjacent to the carbon joining the ring to the rest of the molecule (i.e., as in 2-pyrrolyl), R¹² is preferably attached to a carbon ring member adjacent to the carbon joining the ring to the rest of the molecule.

Halogen represents fluoro, chloro, bromo and iodo.

One or more, preferably one to four, antiviral agents useful in anti-HIV-1 therapy may be used in combination with a CCR5 antagonist of the present disclosure. The antiviral agent or agents may be combined with the CCR5 antagonist in a single dosage form, or the CCR5 antagonist and the antiviral agent or agents may be administered simultaneously or sequentially as separate dosage forms. The antiviral agents contemplated for use in combination with the compounds of the present disclosure comprise nucleoside and nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors and other antiviral drugs listed below not falling within these classifications. In particular, the combinations known as HAART (Highly Active Antiretroviral Therapy) are contemplated for use in combination with the CCR5 antagonists of this disclosure.

The term "nucleoside and nucleotide reverse transcriptase inhibitors" ("NRTI" s) as used herein means nucleosides and nucleotides and analogues thereof that inhibit the activity of HIV-1 reverse transcriptase, the enzyme which catalyzes the conversion of viral genomic HIV-1 RNA into proviral HIV-1 DNA.

Typical suitable NRTIs include zidovudine (AZT) available under the RETROVIR trademark from Glaxo-Wellcome Inc., Research Triangle, NC 27709; didanosine (ddI) available under the VIDEX trademark from Bristol-Myers Squibb Co., Princeton, NJ 08543; zalcitabine (ddC) available under the HIVID trademark from Roche Pharmaceuticals, Nutley, NJ 07110; stavudine (d4T) available under the ZERIT trademark from Bristol-Myers Squibb Co., Princeton, NJ 08543; lamivudine (3TC) available under the EPIVIR trademark from Glaxo-Wellcome Research Triangle, NC 27709; abacavir (1592U89) disclosed in WO96/30025 and available under the ZIAGEN trademark from Glaxo-Wellcome Research

Triangle, NC 27709; adefovir dipivoxil [bis(POM)-PMEA] available under the PREVON tradename from Gilead Sciences, Foster City, CA 94404; lobucavir (BMS-180194), a nucleoside reverse transcriptase inhibitor disclosed in EP-0358154 and EP-0736533 and under development by Bristol-Myers Squibb, 5 Princeton, NJ 08543; BCH-10652, a reverse transcriptase inhibitor (in the form of a racemic mixture of BCH-10618 and BCH-10619) under development by BioChem Pharma, Laval, Quebec H7V, 4A7, Canada; emtricitabine [(-)-FTC] licensed from Emory University under Emory Univ. U.S. Patent No. 5,814,639 and under development by Triangle Pharmaceuticals, Durham, NC 27707; beta-L- 10 FD4 (also called beta-L-D4C and named beta-L-2', 3'-dideoxy-5-fluoro-cytidine) licensed by Yale University to Vion Pharmaceuticals, New Haven CT 06511; DAPD, the purine nucleoside, (-)-beta-D-2,6,-diamino-purine dioxolane disclosed in EP 0656778 and licensed by Emory University and the University of Georgia to Triangle Pharmaceuticals, Durham, NC 27707; and Idenosine (FddA), 9-(2,3- 15 dideoxy-2-fluoro-b-D-threo-pentofuranosyl)adenine, a acid stable purine-based reverse transcriptase inhibitor discovered by the NIH and under development by U.S. Bioscience Inc., West Conshohoken, PA 19428.

20 The term "non-nucleoside reverse transcriptase inhibitors" ("NNRTI's) as used herein means non-nucleosides that inhibit the activity of HIV-1 reverse transcriptase.

Typical suitable NNRTIs include nevirapine (BI-RG-587) available under the VIRAMUNE tradename from Boehringer Ingelheim, the manufacturer for Roxane Laboratories, Columbus, OH 43216; delavirdine (BHAP, U-90152) available under the RESRIPTOR tradename from Pharmacia & Upjohn Co., 25 Bridgewater NJ 08807; efavirenz (DMP-266) a benzoxazin-2-one disclosed in WO94/03440 and available under the SUSTIVA tradename from DuPont Pharmaceutical Co., Wilmington, DE 19880-0723; PNU-142721, a furopyridine-thio-pyrimide under development by Pharmacia and Upjohn, Bridgewater NJ 08807; AG-1549 (formerly Shionogi # S-1153); 5-(3,5-dichlorophenyl)- thio-4- 30 isopropyl-1-(4-pyridyl)methyl-1H-imidazol-2-ylmethyl carbonate disclosed in WO 96 /10019 and under clinical development by Agouron Pharmaceuticals, Inc., LaJolla CA 92037-1020; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6- (phenylmethyl)-(2,4(1H,3H)-pyrimidinedione) discovered by Mitsubishi Chemical Co. and under development by Triangle Pharmaceuticals, Durham, NC 27707; 35 and (+)-calanolide A (NSC-675451) and B, coumarin derivatives disclosed in NIH U.S. Patent No. 5,489,697, licensed to Med Chem Research, which is co-developing (+) calanolide A with Vita-Invest as an orally administrable product.

The term "protease inhibitor" ("PI") as used herein means inhibitors of the HIV-1 protease, an enzyme required for the proteolytic cleavage of viral polyprotein precursors (e.g., viral GAG and GAG Pol polyproteins), into the individual functional proteins found in infectious HIV-1. HIV protease inhibitors 5 include compounds having a peptidomimetic structure, high molecular weight (7600 daltons) and substantial peptide character, e.g. CRIXIVAN(available from Merck) as well as nonpeptide protease inhibitors e.g., VIRACEPT (available from Agouron).

Typical suitable PIs include saquinavir (Ro 31-8959) available in hard gel 10 capsules under the INVIRASE tradename and as soft gel capsules under the FORTOUASE tradename from Roche Pharmaceuticals, Nutley, NJ 07110-1199; ritonavir (ABT-538) available under the NORVIR tradename from Abbott Laboratories, Abbott Park, IL 60064; indinavir (MK-639) available under the CRIXIVAN tradename from Merck & Co., Inc., West Point, PA 19486-0004; 15 nelfnavir (AG-1343) available under the VIRACEPT tradename from Agouron Pharmaceuticals, Inc., LaJolla CA 92037-1020; amprenavir (141W94), tradename AGENERASE, a non-peptide protease inhibitor under development by Vertex Pharmaceuticals, Inc., Cambridge, MA 02139-4211 and available from Glaxo-Wellcome, Research Triangle, NC under an expanded access program; 20 lasinavir (BMS-234475) available from Bristol-Myers Squibb, Princeton, NJ 08543 (originally discovered by Novartis, Basel, Switzerland (CGP-61755); DMP-450, a cyclic urea discovered by Dupont and under development by Triangle Pharmaceuticals; BMS-2322623, an azapeptide under development by Bristol-Myers Squibb, Princeton, NJ 08543, as a 2nd-generation HIV-1 PI; ABT-378 25 under development by Abbott , Abbott Park, IL 60064; and AG-1549 an orally active imidazole carbamate discovered by Shionogi (Shionogi #S-1153) and under development by Agouron Pharmaceuticals, Inc., LaJolla CA 92037-1020.

Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, 30 penta fuside and Yissum Project No. 11607. Hydroxyurea (Droxia), a ribonucleoside triphosphate reductase inhibitor, the enzyme involved in the activation of T-cells, was discovered at the NCI is under development by Bristol-Myers Squibb; in preclinical studies, it was shown to have a synergistic effect on the activity of didanosine and has been studied with stavudine. IL-2 is disclosed in Ajinomoto EP-0142268 , Takeda EP-0176299, and Chiron U. S. Patent Nos. 35 RE 33653, 4530787, 4569790, 4604377, 4748234, 4752585, and 4949314 is available under the PROLEUKIN (aldesleukin) tradename from Chiron Corp., Emeryville, CA 94608-2997 as a lyophilized powder for IV infusion or sc administration upon reconstitution and dilution with water; a dose of about 1 to

about 20 million IU/day, sc is preferred; a dose of about 15 million IU/day, sc is more preferred. IL-12 is disclosed in WO96/25171 and is available from Roche Pharmaceuticals, Nutley, NJ 07110-1199 and American Home Products, Madison, NJ 07940; a dose of about 0.5 microgram/kg/day to about 10

5 microgram/kg/day, sc is preferred. Pentafuside (DP-178, T-20) a 36-amino acid synthetic peptide, disclosed in U.S. Patent No.5,464,933 licensed from Duke University to Trimeris which is developing pentafuside in collaboration with Duke University; pentafuside acts by inhibiting fusion of HIV-1 to target membranes. Pentafuside (3-100 mg /day) is given as a continuous sc infusion or injection
10 together with efavirenz and 2 PI's to HIV-1 positive patients refractory to a triple combination therapy; use of 100 mg/day is preferred. Yissum Project No. 11607, a synthetic protein based on the HIV -1 Vif protein, is under preclinical development by Yissum Research Development Co., Jerusalem 91042 , Israel. Ribavirin, 1- β -D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, is available from
15 ICN Pharmaceuticals, Inc., Costa Mesa, CA; its manufacture and formulation are described in U.S. Patent No. 4,211,771.

The term "anti-HIV-1 therapy" as used herein means any anti-HIV-1 drug found useful for treating HIV-1 infections in man alone, or as part of multidrug combination therapies, especially the HAART triple and quadruple combination therapies. Typical suitable known anti-HIV-1 therapies include, but are not limited to multidrug combination therapies such as (i) at least three anti-HIV-1 drugs selected from two NRTIs, one PI, a second PI, and one NNRTI; and (ii) at least two anti-HIV-1 drugs selected from , NNRTIs and PIs. Typical suitable HAART - multidrug combination therapies include:

25 (a) triple combination therapies such as two NRTIs and one PI ; or (b) two NRTIs and one NNRTI ; and (c) quadruple combination therapies such as two NRTIs , one PI and a second PI or one NNRTI. In treatment of naive patients, it is preferred to start anti-HIV-1 treatment with the triple combination therapy; the use of two NRTIs and one PI is preferred unless there is intolerance to PIs. Drug
30 compliance is essential. The CD4⁺ and HIV-1-RNA plasma levels should be monitored every 3-6 months. Should viral load plateau, a fourth drug,e.g., one PI or one NNRTI could be added. See the table below wherein typical therapies are further described:

ANTI-HIV-1 MULTI DRUG COMBINATION THERAPIES

35 A. Triple Combination Therapies
1. Two NRTIs¹ + one PI²
2. Two NRTIs¹ + one NNRTI³

B. Quadruple Combination Therapies⁴

Two NRTIs + one PI + a second PI or one NNRTI

C. ALTERNATIVES:⁵

Two NRTI¹

One NRTI⁵ + one PI²

Two PIs⁶ ± one NRTI⁷ or NNRTI³

One PI² + one NRTI⁷ + one NNRTI³

FOOTNOTES TO TABLE

1. One of the following: zidovudine + lamivudine; zidovudine + didanosine; stavudine + lamivudine; stavudine + didanosine; zidovudine + zalcitabine

2. Indinavir, nelfinavir, ritonavir or saquinavir soft gel capsules.

3. Nevirapine or delavirdine.

15 4. See A-M. Vandamne et al Antiviral Chemistry & Chemotherapy 9:187 at p 193-197 and Figures 1 + 2.

5. Alternative regimens are for patients unable to take a recommended regimen because of compliance problems or toxicity, and for those who fail or relapse on a recommended regimen. Double nucleoside combinations may 20 lead to HIV- resistance and clinical failure in many patients.

6. Most data obtained with saquinavir and ritonavir (each 400 mg bid).

7. Zidovudine, stavudine or didanosine.

25 Agents known in the treatment of rheumatoid arthritis, transplant and graft v. host disease, inflammatory bowel disease and multiple sclerosis which can be administered in combination with the CCR5 antagonists of the present disclosure (including the compound of the present invention) are as follows:

solid organ transplant rejection and graft v. host disease: immune suppressants such as cyclosporine and Interleukin-10 (IL-10), tacrolimus,

30 antilymphocyte globulin, OKT-3 antibody, and steroids;

inflammatory bowel disease: IL-10 (see US 5,368,854), steroids and azulfidine;

rheumatoid arthritis: methotrexate, azathioprine, cyclophosphamide, steroids and mycophenolate mofetil;

35 multiple sclerosis: interferon-β₁, interferon-α, and steroids.

Certain compounds of the disclosure may exist in different isomeric forms (e.g., enantiomers, diastereoisomers, atropisomers and rotamers). The disclosure

contemplates all such isomers both in pure form and in admixture, including racemic mixtures.

Certain compounds will be acidic in nature, e.g. those compounds which possess a carboxyl or phenolic hydroxyl group. These compounds may form

5 pharmaceutically acceptable salts. Examples of such salts may include sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, N-methylglucamine and the like.

Certain basic compounds also form pharmaceutically acceptable salts,

10 e.g., acid addition salts. For example, the pyrido-nitrogen atoms may form salts with strong acid, while compounds having basic substituents such as amino groups also form salts with weaker acids. Examples of suitable acids for salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other
15 mineral and carboxylic acids well known to those in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. The free base forms may be regenerated by treating the salt with a suitable dilute aqueous base solution such as dilute aqueous NaOH, potassium carbonate, ammonia and sodium
20 bicarbonate. The free base forms differ from their respective salt forms somewhat in certain physical properties, such as solubility in polar solvents, but the acid and base salts are otherwise equivalent to their respective free base forms for purposes of the disclosure.

All such acid and base salts are intended to be pharmaceutically


25 acceptable salts within the scope of the disclosure and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the disclosure.

Compounds of the disclosure can be made by the procedures known in
30 the art, for example by the procedures described in the following reaction schemes, by the methods described in the examples below, and by using the methods described in WO96/26196 and WO98/05292.

The following solvents and reagents may be referred to herein by the abbreviations indicated: tetrahydrofuran (THF); ethanol (EtOH); methanol
35 (MeOH); acetic acid (HOAc or AcOH); ethyl acetate (EtOAc); N,N-dimethylformamide (DMF); trifluoroacetic acid (TFA); 1-hydroxy-benzotriazole (HOBT); m-chloroperbenzoic acid (MCPBA); triethylamine (Et₃N); diethyl ether (Et₂O); dimethylsulfoxide (DMSO); and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (DEC). RT is room temperature, and TLC is thin-layer

chromatography. Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl, Ph is phenyl, and Ac is acetyl.

Scheme 1



Reagents and conditions: a: $R^4CH(OSO_2CF_3)CO_2CH_3$, base (e.g., K_2CO_3); b: $ClCH_2COCl$; c: NH_3 ; d: $NaBH_4-BF_3$; e: N -Boc-4-piperidone, $NaBH(OAc)_3$; f: CF_3CO_2H ; g: acylation; h: N -Boc-4-piperidone, $Ti(OPr-i)_4$, Et_2AlCN ; i: CH_3MgBr .

In **Scheme 1**, a benzylamine (1), wherein R and R^3 are as defined above and R^1 is hydrogen, is converted via (2) and (3) to the diketopiperazine (4), wherein R^4 is as defined above, which is reduced to the piperazine (5).


Depending upon the desired R^6 substituent, this is processed in two ways.

15 Reductive amination gives (6), which can be deprotected to (7) and finally acylated to the compounds of formula IA wherein R^5 and R^6 are H; alternatively, a modified Strecker reaction on (5) gives the aminonitrile (8), which, after treatment with methyl Grignard to give (9), deprotection to (10) and final N-acylation affords the compounds of formula IB wherein R^5 is H and R^6 is methyl.

20 Acylation of (7) and (10) is carried out under standard conditions, e.g., with a compound R^2COOH and reagents such as DEC and HOBT. Use of a chiral

compound of formula 1, e.g., (S)-methyl 4-substituted benzylamine, and a chiral lactate in step a, e.g., methyl (R)-lactate triflate, will result in chiral compounds of formulas IA and IB.


5 **Scheme 2**




Reagents: j: oxaborazolidine, BH_3 ; k: $\text{CH}_3\text{SO}_2\text{Cl}$, base; I: $\text{CF}_3\text{CO}_2\text{H}$.

In **Scheme 2**, the compounds are prepared by an alkylation process on a pre-formed piperazine derivative. For example, preferred compounds with the S,S stereochemistry may be obtained in this way by chiral reduction of a ketone (11) to the alcohol (12), activation as the mesylate, and displacement with inversion by treatment with a suitable piperazine, which may either be mono-protected, in which case final elaboration requires deprotection followed by the steps described in (e) - (g) in Scheme 1 to obtain IC, or may be elaborated prior to the displacement step, in which case the final steps are (f) and (g) (deprotection and acylation) as in Scheme 1 to obtain ID.


Scheme 3




20 For compounds where R^3 and R^1 are each H, either the alkylation route of Scheme 2 or a reductive amination method as typified in Scheme 3 can be used.

Scheme 4


For diaryl compounds, wherein R and R³ are each aryl, an alkylation method as typified in Scheme 4 is preferred.

Scheme 5

Piperazines of formula 14, especially those wherein R³ is C₂-C₆ alkyl or




benzyl, may also be obtained by a process wherein the portion is introduced as shown above by an alkylation-decyanation sequence. The reaction is exemplified for compounds wherein R is CF₃O-phenyl, R¹ is hydrogen, R³ is ethyl and R⁴ is methyl, but using appropriate starting materials, other compounds of formula 14 can be similarly prepared.

Scheme 6

Reagents: m: BOC₂O, base; n: R⁶MgBr; o: CCl₃CO₂H, NaBH₃CN; p: CF₃CO₂H; q: NaBH₄, BF₃.

As shown in Scheme 6, compounds bearing an additional alkyl group at R⁵ on the piperazine ring may be prepared from the diketopiperazine intermediates (4) of Scheme 1. (4) is activated by conversion to the N(t-butoxycarbonyl) compound (17); addition of a Grignard reagent and sequential reduction, deprotection and lactam reduction provides (21), which can be used to prepare compounds of formula I in the manner described for intermediate (5) in Scheme 1.


Scheme 7



Many piperazines wherein R is R⁸-phenyl (or their Boc derivatives) shown in Scheme 1 can be obtained from a common intermediate, wherein R⁸ is I. Several examples are shown in the above scheme, wherein R⁸ is converted to Cl, CN, -C(O)NH₂, H, Ph and p-ClC₆H₄CH₂-.

Detailed procedures for these conversions are provided in the examples below. The resultant piperazine or BOC-piperazine is then treated as shown in Scheme 1.


Scheme 8



Some compounds disclosed herein may be obtained by a Mannich method, as shown in the specific example of Scheme 8.

Compounds disclosed herein are exemplified by the following preparative examples, which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures may be apparent to those skilled in the art.

Example 1



Step 1 : Stir methyl R-lactate (5.0 g) in CH_2Cl_2 (40 ml) at -70°C and add

5 trfluoromethanesulfonic anhydride (7.6 ml), then 2,6-lutidine (7.8 ml). Remove the cooling, stir 0.5h, wash with 2N HCl and add the organic solution to (S)-methyl 4-bromobenzylamine (9.0 g) and K_2CO_3 (11.2 g) in water (60 ml). Stir 20h at RT, dry the organic phase over K_2CO_3 , evaporate and chromatograph on silica gel with $\text{Et}_2\text{O-CH}_2\text{Cl}_2$ to give the desired product (7.50 g) as a thick oil.

10 Step 2: Reflux the product of step 1 (7.5 g) in 1,2-dichloroethane (40 ml) and ClCH_2COCl (5.0 ml) for 5h, then evaporate and use the resultant residue directly in the next step.

Step 3: Stir the product of step 2 in DMSO (80 ml), water (10 ml) and NaI (8 g), cool in ice, add conc. NH_4OH solution (15 ml) and stir to RT for 20h. Add water

15 (200 ml) dropwise, collect the solid, wash well with water and dry at $70^\circ\text{C}/5\text{ mm}$ to give the diketopiperazine, suitable for the next step.

Step 4: Stir a mixture of the product of step 3 (6.8 g), 1,2-dimethoxyethane (60 ml) and NaBH_4 (3.4 g) under N_2 , add $\text{BF}_3\cdot\text{OEt}_2$ (6.8 ml) dropwise, then heat at 100°C for 10h. Cool and add CH_3OH (20 ml) dropwise, followed by conc. HCl (30 ml). Heat at 100°C for 1h., cool, basify with excess 2N NaOH and extract with EtOAc . Dry over K_2CO_3 and evaporate to obtain the piperazine (5.85 g), suitable for the next step.

Step 5: Stir for 20h. at RT a mixture of the product of step 4 (5.48 g), N-Boc-4-piperidinone (4.32 g), HOAc (1.15 ml), CH_2Cl_2 (80 ml) and sodium triacetoxy-

25 borohydride ($\text{NaBH}(\text{OAc})_3$) (8.3 g). Add excess aqueous Na_2CO_3 solution slowly, stir for 0.5h, separate and filter the organic phase through a pad of silca gel, washing with 10:1 $\text{CH}_2\text{Cl}_2\text{-Et}_2\text{O}$ to elute all of the product. Evaporate and dissolve the residue in Et_2O (100 ml). Stir and add a 4M solution of HCl in 1,4-dioxane (10 ml) dropwise. Collect the solid, wash with Et_2O , and stir with CH_2Cl_2 and excess aqueous NaOH. Dry the organic phase over K_2CO_3 and evaporate to obtain the desired product (5.45 g).

Step 6: Stir at RT for 2h a mixture of the product of step 5 (1.5 g) and TFA (4 ml). Evaporate, dissolve in CH_2Cl_2 and wash with excess 1N NaOH solution. Dry over K_2CO_3 and evaporate to obtain the product (1.15 g).


Compound 1A: Following the standard procedure, react the product of step 6 with 2,6-dimethylbenzoyl chloride in CH_2Cl_2 and aqueous NaOH, and convert the product to the hydrochloride. Mp 185-192° C (decomposition). HRMS found: 498.2130; MH^+ Calc: 498.2120.

5 Compound 1B: Following the standard procedure, couple the product of step 6 with 2-amino-6-methylbenzoic acid using HOBT and DEC with diisopropylethylamine in DMF, purify the amide by preparative TLC and convert to the hydrochloride. Mp 188-196° C (decomposition). HRMS found: 499.2069; MH^+ Calc: 499.2072.

10 Compound 1C: Following the above method, couple the product of step 6 with 2-amino-6-chlorobenzoic acid and convert after purification to the hydrochloride. Mp 192-200° C (decomposition). HRMS found: 519.1530; MH^+ Calc: 519.1526.

Example 2

15



Step 1: Stir the product of Example 1, step 4 (1.00 g), N-t-butoxycarbonyl-4-piperidinone (0.77 g) and titanium (IV) isopropoxide ($\text{Ti}(\text{O}i\text{Pr})_4$) (1.00 g) for 20h at RT in CH_2Cl_2 (15 ml), reflux for 3h and cool to RT. Add diethylaluminum cyanide (Et_2AlCN) (4.2 ml of 1M toluene solution) and stir for 5 days at RT under dry N_2 . Workup in CH_2Cl_2 -aq. NaOH, dry and evaporate the organic phase and chromatograph on silica gel with $\text{CH}_2\text{Cl}_2\text{-CH}_3\text{OH}$ (100:1) to obtain the desired product (0.72 g).

20 Step 2: React the product of step 1 (0.70 g) in dry THF (15 ml) under N_2 with CH_3MgBr (4 ml of 3M Et_2O solution) at RT for 20h. Workup in EtOAc-water and filter the organic phase through silica gel, washing with EtOAc. Evaporate to obtain the desired product (0.65 g).

25 Step 3: Deprotect the product of step 2 with TFA according to the procedure described in Example 1, step 6.

30 Compound 2A: React the product of step 3 with dimethylbenzoyl chloride as described in Example 1 and convert to the HCl salt. Mp 180-187° C (decomposition). HRMS Found: 512.2272; MH^+ Calc: 512.2276.

Compound 2B: React the product of step 3 with 2-amino-6-chlorobenzoic acid as described in Example 1, purify the crude product by preparative TLC and

convert to the HCl salt. Mp 195-200° C (decomposition). HRMS Found: 535.1662; MH^+ Calc: 535.1652.


Compound 2C: React the product of step 3 with 2-hydroxy-6-methylbenzoic acid as described in Example 1, purify the crude product by preparative TLC and

5 convert to the HCl salt. Mp 206-210° C (decomposition). HRMS Found: 514.2067; MH^+ Calc: 514.2069.

Compound 2D: React the product of step 3 with 2-amino-6-methylbenzoic acid using a procedure similar to that described in Example 1, purify the crude product by preparative TLC and convert to the HCl salt. Mp 202-209° C (decomposition).

10 HRMS Found: 513.2227; MH^+ Calc: 513.2229.

Example 3



15 Step 1: Reflux and stir a mixture of S-alanine methyl ester hydrochloride (14 g), anhydrous Na_2CO_3 (60 g), dry CH_3CN (125 ml), chlorodiphenylmethane (22.3 g) and NaI (5 g) for 6 hr. Cool, add ice- H_2O and extract with Et_2O (350 ml, then 50 ml). Combine the Et_2O extracts and wash with portions of 1N aq. HCl: 200 ml, 100 ml, then 4 x 10 ml. Combine the aqueous acid extracts, stir and add excess 20 Na_2CO_3 in small portions until the mixture is basic. Extract with Et_2O , dry over MgSO_4 and evaporate to obtain the N-diphenylmethyl compound (23.2 g).

Step 2: Reflux all of the above compound with ClCH_2COCl (10 ml) in dichloroethane (60 ml) for 4 h. Evaporate, and co-evaporate with toluene (20 ml). Dissolve the residue in CH_2Cl_2 (200 ml), stir for 0.5 h with activated carbon (10

25 g), filter and evaporate. Stir the residue with ice cooling in DMSO (200 ml) and gradually add concentrated aqueous NH_3 (100 ml), then NaI (10 g). Stir at RT for 20 hr. Add iced water (500 ml), collect the solid, wash well with water, then with several small portions of a 10:1 hexane- Et_2O mixture, and dry at 50° C with high vacuum to obtain the solid diketopiperazine (15.5 g). Recrystallise a small 30 sample from CH_2Cl_2 -hexanes: mp 186-188° C; $[\alpha]_D^{20} = +272.6^\circ$.

Step 3: Stir the product of step 2 (4.0 g) in dimethoxyethane (40 ml) and NaBH_4 (1.6 g) under N_2 and add $\text{BF}_3\text{-OEt}_2$ (3.2 ml) slowly. Reflux for 20 h. Cool and add CH_3OH (10 ml) dropwise, then conc. HCl (15 ml). Reflux for 2 h., and work

up in excess 2N aq. NaOH and extract with CH_2Cl_2 . Dry over K_2CO_3 and evaporate. Chromatograph on silica, eluting with $\text{CH}_2\text{Cl}_2\text{-CH}_3\text{OH}$ mixtures, and finally with 5:1:0.1 v/v/v $\text{CH}_2\text{Cl}_2\text{:CH}_3\text{OH:NH}_4\text{OH}$. Combine and evaporate the product fractions to obtain the desired product (1.95 g) as a pale yellow gum.

5 Step 4: Stir a mixture of the product of step 3 (0.50 g), N-allyloxycarbonyl-4-piperidone (0.40 g), CH_2Cl_2 (5 ml) and $\text{NaBH}(\text{OAc})_3$ (0.70 g) at RT for 20 h. Work up in CH_2Cl_2 and excess aq. NaOH, dry over MgSO_4 , evaporate and isolate the product by preparative TLC, eluting with 10% Et_2O in CH_2Cl_2 , to obtain the desired compound (0.80 g) as an oil, contaminated with a small

10 amount of starting ketone, but suitable for the next step.


Step 5: Stir a mixture of the product of step 4 (0.80 g), CH_3CN (20 ml), water (5 ml) and piperidine (1.5 ml). Add tri(4-sulfophenyl)phosphine (0.072 g) and palladium (II) acetate (0.02 g) and stir at RT under N_2 for 2 h. Work up with aqueous NaOH, extract with 5:1 v/v toluene: CH_2Cl_2 , dry over K_2CO_3 and evaporate to obtain a yellow oil, suitable for acylation.

Compound 3A: Stir and reflux a mixture of the product of step 5 (0.10 g), N-(2,6-dimethoxybenzoyl)-4-piperidinone (0.10 g), CH_2Cl_2 (2 ml) and $\text{NaBH}(\text{OAc})_3$ (0.15 g) for 2.5 h., cool, and work up with CH_2Cl_2 and aqueous NaOH. Dry over MgSO_4 , evaporate and isolate the major product by preparative TLC, eluting with 3:1 v/v $\text{Et}_2\text{O}:\text{CH}_2\text{Cl}_2$. Precipitate the hydrochloride to obtain the desired compound as the HCl salt (0.13 g). Mp 173-177° C (decomposition). HRMS Found: 482.3175; MH^+ Calc: 482.3171.


Compound 3B: Couple the product of step 5 with 2-amino-6-chlorobenzoic acid using DEC-HOBt as described in Example 1, isolate the product by PTLC and precipitate the hydrochloride to give compound 3B. Mp 188-195° C (decomposition). HRMS Found: 503.2567; MH^+ Calc: 503.2578.

Compound 3C: Couple the product of step 5 with 2,4-dimethylnicotinic acid using DEC-HOBt as described above, isolate the product by PTLC and precipitate the hydrochloride to give compound 3C. Mp 180-188° C (decomposition). HRMS Found: 483.3114; MH^+ Calc: 483.3124.


Using procedures similar to those described above, the following compounds were prepared:



3D: Mp. 85-89°C; HRMS (MH⁺) found: 496.3343




3E: Mp. 170-175°C



3F: Mp. 180-185°C

5

Example 4



Step 1: A solution of 4-trifluoromethyl acetophenone (1.88 g; 10 mmol) in dry THF (10 ml) was cooled in an ice bath and treated with freshly prepared solid (S)-

10 2-methyl oxaborolidine (0.54g; 2 mmol). After 10 min., a solution of 2M borane-methyl sulfide complex (3 ml; 6 mmol) in THF was added dropwise over 5 min.

TLC at the end of 30 min. showed that the starting material had been converted to a more polar product. The reaction was quenched with about 5 ml of CH₃OH carefully until effervescence stopped; volatiles were removed in vacuo. The

15 residue was dissolved in CH₂Cl₂ and washed with 1N HCl, water, 10% NaHCO₃ solution and brine. Concentration in vacuo gave 2g of a yellow gum. Flash silica gel chromatography (FSGC) using 10-20% EtOAc in hexanes furnished the desired chiral alcohol (1.6 g; 84%) as a colorless oil. TLC R_f = 0.6 in 25% EtOAc:hexanes.

20 **Step 2:** To a solution of the product of step 1(1.55g; 8.16 mmol) in 10 ml of CH₂Cl₂ cooled in an ice bath were added Et₃N (2.3 ml; 16.32 mmol) and

$\text{CH}_3\text{SO}_2\text{Cl}$ (0.87 ml; 10.6 mmol) to form a turbid white solution. The reaction was quenched with water and the organic product was extracted with CH_2Cl_2 , washing with water, 1N HCl, 10% NaHCO_3 solution and brine. Concentration in vacuo gave the chiral mesylate (2.1g; 96%) as a pale yellow oil. TLC R_f = 0.6 in 25%

5 EtOAc:hexanes.

Step 3: A solution of the product of step 2 (2.1g; 7.8 mmol), the N-BOC protected 2(S)-methyl piperazine (1.56g; 7.8 mmol - prepared from the reaction of commercial 2(S)-methyl piperazine with N-(tert-butoxy-carbonyloxy)phthalimide) and 2,2,6,6-tetramethyl piperidine (1.34 ml; 8 mmol) in 14 ml of dry CN_3CN were

10 heated at reflux until TLC indicated complete disappearance of the mesylate (16 h). The reaction mixture was cooled to RT, diluted with CH_2Cl_2 (50 ml) and washed with water (3 x 100 ml) and brine. The organic extract was dried over solid MgSO_4 and then concentrated to obtain 2.8 g of a yellow gum. FSGC (20% EtOAc in hexanes) served to isolate the desired (S,S)-diastereomer (1.5g; 52%)
15 and its benzylic epimer, the (R,S)-diastereomer (0.5g; 17%) for a combined 69% yield. TLC R_f = 0.75 (S,S) and 0.56 (R,S) in 25% EtOAc:hexanes.

Step 4: TFA (6 ml) was added to a solution of the product of step 3 in 12 ml of CH_2Cl_2 and the resulting yellow-orange solution was stirred at RT for 8 h. The reaction was quenched by adding 1N NaOH solution to adjust the pH to 10.

20 Extractive work up in CH_2Cl_2 gave 1.1g of a yellow syrup. FSGC using 10% CH_3OH in CH_2Cl_2 removed the less polar impurity and gradient elution with 1% Et_3N in 10% $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$ was needed to elute the desired free amine of the (S,S) diastereomer. Yield = 0.9g (75%). TLC R_f = 0.5 in 10% $\text{CH}_3\text{OH}:\text{CH}_2\text{Cl}_2$.

25 Step 5: A colorless solution of the product of step 4 (0.9g; 3.3 mmol), 4-piperidinone (0.86g; 4.3 mmol), $\text{NaB}(\text{OAc})_3\text{H}$ (1.05g; 4.95 mmol) and glacial AcOH (80 μl) in 8 ml of CH_2Cl_2 was stirred at ambient temperature for a day. TLC indicated absence of starting material. The reaction mixture was diluted with 50 ml of CH_2Cl_2 , washed with 1N NaOH solution, water (2 x) and brine. The CH_2Cl_2 extract was dried over anhydrous MgSO_4 and concentrated to obtain 30 1.7g of yellow oil. FSGC (25% acetone in hexanes) was used to isolate the pure product (1.3g; 86%) as a white foam. TLC R_f = 0.6 in 25% acetone/hexanes.


35 Step 6: TFA (5 ml) was added to a solution of the product of step 5 (1.3g; 2.87 mmol) in CH_2Cl_2 (10 ml) and the resulting yellow orange solution was stirred at RT for 7 h. The reaction was quenched with 1N NaOH solution and the pH was adjusted to 10. The organic product was extracted into 50 ml of CH_2Cl_2 and washed with water, then brine and dried over MgSO_4 . Concentration gave the free amine (0.98g; 98%) as a yellow syrup. TLC R_f = 0.1 in 25% acetone/hexanes.

Step 7: The product of step 6 (0.78g; 2.21 mmol), DEC (0.65g; 3.4 mmol), HOBT (0.46g; 3.4 mmol) and 2-amino-6-chloro benzoic acid (0.51g; 2.9 mmol) were dissolved in 8 ml of CH_2Cl_2 to which was added diisopropylethyl amine (0.7 ml) and the mixture was stirred at ambient temperature for 16h. TLC analysis

5 showed absence of starting material and formation of two over-lapping spots of medium polarity (rotomers of the hindered amide) as the major product. The crude product (1.3g) was isolated by extractive work up and purified through FSGC using 25% acetone in CH_2Cl_2 as eluant to give the title compound (0.88g; 80%) as a pale yellow foam. TLC R_f = 0.45 and 0.5 in 25% acetone: CH_2Cl_2 .




10 A solution of hydrogen chloride in Et_2O (1M; 3 ml) was added to a solution of the title compound free base (0.76g; 1.54 mmol) in CH_2Cl_2 (5ml) to obtain an instantaneous white precipitate. After stirring at RT for 2 h, the volatiles were removed on a rotary evaporator and the white residue was suspended in dry toluene (3 x 10 ml) and azeotroped. The white solid thus 15 obtained was suspended in dry Et_2O containing 10% EtOAc, stirred for 30 min, filtered and washed with Et_2O (100 ml). The HCl salt of the title compound was dried under high vacuum to yield an off-white solid (0.88g; 95%). Mp: 205-210° C.

20 The product of step 6 was converted to other amides (4A-4E) as described in step 7 using the appropriate carboxylic acids. Physical data for compounds 4-4E having the following structures is as follows:




wherein R⁸ and R² are as defined in the table:

Ex.	R ⁸	R ²	Mp (°C)	HRMS (MH ⁺)
4	CF ₃		205-210	509.2295
4A	CF ₃		192-195	489.2841
4B	CF ₃		203-206	490.2681
4C	CF ₃		186-190	488.2902


4D	CF ₃		207-210	489.2851
4E	CF ₃		152	505
4F	CF ₃		--	490.2796

Example 5












5


A solution of the racemic benzyl chloride **24** (1.26g, 5.62 mmol) which was prepared freshly from the corresponding carbinol, the 2(S)-methyl piperazine (1.12g, 5.62 mmol) and 2,2,6,6-tetramethyl piperidine (TMP) (1.9 ml, 11.2 mmol) were dissolved in dry DMF (2 ml) and heated to 100-110°C (internal temp.) for 10 h. TLC analysis showed absence of **24** and formation of two well-separated products. The mixture was diluted with water and the organics were extracted into Et₂O. The organic extract was washed with saturated NH₄Cl and brine and concentrated in vacuo to obtain 2 g of crude product. Flash chromatography on silica gel and elution first with 25% Et₂O-hexane followed by 25% EtOAc-hexane gave ~0.5 grams of **25a** and ~0.5 grams of **25b** respectively (~45% combined yield). TLC R_f = 0.6 (for **25a**) and 0.4 (for **25b**) in 25% EtOAc-hexanes. Purified **25a** was treated as described previously to obtain the final products 5 to 5F having the formula .



20 wherein R² is as defined in the table:


Ex.	R ²	mp (°C)	HRMS
5		208-212	519.2958
5A		198-203	535.2913
5B		233 (sharp)	539.2390
5C		190	575.1800
5D		253	558.1887
5E		202	519.2964
5F		190	535.2901
5G		198-203	--
5H		205-210	--

Example 6




5

Step 1:



28





A mixture of the aldehyde **26** (3.9g, 20.5 mmol), the 2(S)-methyl-N-BOC-piperazine (4.1 g, 20.5 mmol) and $Ti(OiPr)_4$ (6.1 mL; 20.5 mmol) in 40 ml of CH_2Cl_2 was stirred at RT for 24 h. Et_2AlCN was introduced and stirred for an 5 additional day. The reaction mixture was processed as described before to obtain 4.71 grams (58%) of the cyano amine **27** after FSGC (TLC R_f = 0.45/0.5 for diastereomers seen with 25% Et_2O -hexanes as solvent).



Step 2: Sodium hexamethyldisilazide (1M; 3.1 ml) was added to a solution of **27** (1g; 2.5 mmol) in dry THF cooled in a dry ice/acetone bath. The resulting bright 10 yellow solution was treated with CH_3CH_2I (7.5 mmol; 0.6 ml). The dry ice bath was removed and the reaction was stirred at ambient temperature for 15 min. followed by gentle warming in a warm water bath (40°C) for 30 min. TLC indicated two well-separated spots. Standard extractive work up and purification by FSGC gave two alkylated compounds (combined yield: 0.7g; 70%). TLC R_f = 15 0.6 and 0.4 (25% $EtOAc$ /hexanes).

Step 3: The product of step 2 was stirred with $NaBH(OAc)_3$ (2x) and $MgBr_2:OEt_2$ (1x) in CH_3CN for a day. The reaction mixture was quenched with water, the 20 organics were extracted into $EtOAc$ and processed to obtain 0.8 grams of crude product. FSGC (25% $EtOAc$ -hexanes) gave ~0.4 grams of each diastereomer (combined yield ~100%). TLC R_f = 0.55 (**28a**) and 0.45 (**28b**) in 25% $EtOAc$ -hexanes.

Step 4: Compound **28a** (S,S-diastereomer) was processed through the usual 5 step sequence to complete the synthesis of compounds of Example 6, 6A and 6B with an ipso-methyl group as well as compounds 6C and 6D which lack the ipso- 25 methyl group:




Ex.	R ⁶	R ²	mp (°C)	MS (MH ⁺)
6	CH ₃		204	549.5





6A	CH ₃		253	589.4
6B	CH ₃		260	534.4
6C	H		225	520.4
6D	H		215	575.4






Example 7

The synthesis of compounds with an alkyl or arylsulfonyl R⁸ group at the para position started with the corresponding para-substituted acetophenone which was treated as in Example 4, steps 1-6 to obtain the sulfone containing compounds of Example 7 having the formula:




wherein R^8 and R^2 are as defined in the table:

Ex.	R ⁸	R ²	Mp (°C)	HRMS (MH ⁺)
7	H ₃ CSO ₂ -		220-225	498.2790
7A	H ₃ CSO ₂ -		212-215	519.2197
7B			190 (dec.)	604.2861
7C			178 (dec.)	625.2246
7D			170 (dec.)	605.2799
7E			170 (dec.)	609.2540

7F			200 (dec.)	612.2336
7G			158 (dec.)	644.1735
7H	H_3CSO_2^-		197 (dec.)	514.2847

Example 8



5 Step 1: A solution of the product of Example 4, step 4 (1.25g; 4.6 mmol), N-BOC-4-piperidinone (0.91g; 4.6 mmol) and (Ti(OiPr)₄) (1.4 ml; 4.6 mmol) in 10 ml of CH₂Cl₂ was stirred at ambient temperature for 24 h. The reaction mixture was then treated with Et₂AlCN (5.5 ml; 1M solution in toluene) and stirring continued for 20 h. The reaction mixture was diluted with EtOAc and stirred with saturated NaHCO₃ solution (10 min.) and the layers were separated as much as possible.

10 The turbid (from inseparable aqueous layer) organic layer was treated with excess celite and filtered, washing the filtercake with EtOAc. The filtrate layers were separated and the organic layer was washed with water and brine, dried over anhydrous MgSO₄ and concentrated to obtain 2.16g (98%) of an amber gum.

15 Step 2: The Strecker amine from step 1 (2.16g) was dissolved in dry THF, cooled in an ice bath and treated with CH₃MgBr (7.5 ml of a 3M solution in Et₂O). After 1 h, the ice bath was removed and the yellow, heterogeneous reaction mixture was stirred at RT for 18h. The reaction was quenched with saturated NH₄Cl solution, 20 diluted with water and extracted with CH₂Cl₂. Concentration gave 2.2 g of a yellow gum which was purified by FSGC, eluting the major product away from more polar impurities using a 1:1 mixture of CH₂Cl₂:EtOAc. The ipso-methyl compound was isolated as a yellow gum (1.85g; 88%). TLC R_f = 0.5 in 1:1 Et₂O:hexanes.

25 Step 3: TFA (6 ml) was added to a solution of the product of step 2 (1.5g; 3.2 mmol) in 10 ml of CH₂Cl₂ and stirred at 25° C for 2 h. The reaction was quenched with 1N NaOH solution to a pH of 9-10 and processed by extraction into CH₂Cl₂ to obtain 1.2 g of crude product. FSGC using 1:1 CH₂Cl₂:EtOAc


removed all the less polar impurities and gradient elution with 10% CH₃OH in CH₂Cl₂ and finally with 10% (ca. 7N-NH₃) CH₃OH in CH₂Cl₂ led to the isolation of the free piperidine as a yellow gum (1.07g; 90%). TLC R_f = 0.2 in 10% CH₃OH:CH₂Cl₂.

5 **Step 4:** A solution of the product of step 3 (1.03g; 2.8 mmol), 2,4-dimethyl nicotinic acid (0.42g; 2.8 mmol), DEC (0.8g; 4.2 mmol), HOBT (0.57g; 4.2 mmol) and diisopropyl ethyl amine (1ml; 5.6 mmol) in CH₂Cl₂ (15 ml) was stirred at 25° C for 24 h. The reaction mixture was diluted with CH₂Cl₂ (25 ml), washed with water, 10% NaHCO₃ solution and brine, then concentrated to obtain 1.6g of crude 10 oil. FSGC of this material using gradient elution with 10% acetone-CH₂Cl₂ followed by 2-5% CH₃OH in CH₂Cl₂ gave the title compound (1.1g; 80%) as a white foam.

TLC R_f = 0.45 in 5% CH₃OH-CH₂Cl₂.

15 The free base of the title compound (1g; 2 mmol) isolated above was dissolved in a 1:1 mixture of EtOAc:Et₂O (8 ml) and a fresh solution of hydrogen chloride in Et₂O (6.1 ml of a 1M solution) was added, instantly forming a white precipitate. After stirring at 25° C for 1h, the volatiles were removed in vacuo. The product was suspended in Et₂O and filtered, washing the filtrate with Et₂O. 20 The HCl salt of the title compound thus obtained was dried in vacuo (1.1g; mp. 213-215° C). HRMS (MH⁺) 503.2997.

The following amides 8A-8E were prepared in a similar manner from the product of step 3 using appropriate acids, and compounds 8F-8H, wherein the R⁸-substituent is a *p*-methyl sulfonyl group were similarly prepared.




25 wherein R⁸ and R² are as defined in the table:

Ex.	R ⁸	R ²	Mp (°C)	HRMS (MH ⁺)
8A	CF ₃		216	503.3021
8B	CF ₃		222-224	504.2850
8C	CF ₃		262-263	502.3039


8D	CF ₃		216-218	523.2466
8E	CF ₃		210-212	519.2970
8F	-SO ₂ CH ₃		201-205	512.2955
8G	-SO ₂ CH ₃		217-221	533.2355
8H	-SO ₂ CH ₃		216-219	514.2736
8I	-CF ₃		195-198	--
8J	-CF ₃		250-255	528.1791
8K	-CF ₃		223-226	576.1562
8L	-CF ₃		>245	528.2439
8M	-CF ₃		176-181	570.1739
8N	-CF ₃		218-223	708.0040
8O	-CF ₃		215-220	522.2507
8P	-CF ₃		208-212	566.1987
8Q	-CF ₃		190-194	586.1442

8R	-CF ₃		255-257	526.2243
----	------------------	-----------------------------------------------------------------------------------	---------	----------

Using procedures described following the table, compounds 8S-8EE of the structure



5 were prepared, wherein R^{11} is defined in the table:

Ex.	R ¹¹	Mp (°C)	HRMS (MH ⁺)
8S	-OH	210-220 (2xHCl salt)	518.2997
8T	-OC(O)NHCH ₂ CH ₃	205-210 (2xHCl salt)	589.3374
8U	-OSO ₂ CH ₃	165-171 (2xHCl salt)	596.2757
8V		199-204 (2xHCl salt)	595.3254
8W	-CHO	88-92	530.2985
8X	-CH=NH-OCH ₃	202-205 (2xHCl salt)	559.3260
8Y	-CHF ₂	>245 (dec) (2xHCl salt)	552.3020
8Z	-NH-C(O)-NH-CH ₂ CH ₃	214-219 (2xHCl salt)	588.3521
8AA	-NH ₂	92-98	517.3154
8BB	-NHSO ₂ CH ₂ CH ₃	205-211 (2xHCl salt)	609.3078
8CC	-F	212-217 (2xHCl salt)	520.2949
8DD	-Cl	235-238 (2xHCl salt)	536.2663
8EE	-Br	237-240 (2xHCl salt)	580.2141

8S: The tri-hydrochloride salt of the product of Example 8, step 3 (75 mg, 0.16 mmol), EDC (61 mg, 0.32 mmol), HOBT (49 mg, 0.32 mmol), iPr₂NEt (0.16 ml, 0.96 mmol), and 2,6-dimethyl-4-hydroxy-benzoic acid (53 mg, 0.32 mmol) were taken up in CH₂Cl₂ and stirred at 25 °C for 20 h. The solution was concentrated.


10 Purification via preparative TLC (EtOAc, SiO₂) gave the title compound as a yellow oil. m.p. (2xHCl salt) 210-220 °C. HRMS (MH⁺) calcd. for C₂₉H₃₉O₂N₃F₃, 518.2994; Found, 518.2997.

8T: **8S** (100 mg, 0.19 mmol), ethyl isocyanate (0.05 ml, 0.58 mmol), and Et_3N (0.13 ml, 0.95 mmol) were taken up in CH_2Cl_2 and stirred at 25 °C for 16 h. The solution was diluted with CH_2Cl_2 and washed with 1 N NaOH. The organic layer was dried (Na_2SO_4), filtered, and concentrated. Purification via preparative TLC (2/1 EtOAc/hexanes, SiO_2) gave the title compound as a yellow oil.

8U: **8S** (250 mg, 0.48 mmol), methane sulfonyl anhydride (250 mg, 1.44 mmol), and NaH (38 mg, 60 wt% in oil) were taken up in THF and stirred at 25 °C for 20 h. The solution was diluted with EtOAc and washed with sat'd NaHCO_3 . The organic layer was dried (Na_2SO_4), filtered, and concentrated. Purification via preparative TLC (1/1 EtOAc/hexanes, SiO_2) gave the title compound as a yellow oil (280 mg, 98%).

8V: The tri-hydrochloride salt of the product of Example 8, step 3 (50 mg, 0.1 mmol), EDC (38 mg, 0.2 mmol), HOBT (27 mg, 0.2 mmol), iPr₂NEt (0.07 ml, 0.4 mmol), and 2,6-dimethyl-4-(4-pyridyl-N-oxide)-benzoic acid (73 mg, 0.3 mmol) (see preparation below) were taken up in CH_2Cl_2 and stirred at 25 °C for 19 h. The solution was concentrated. Purification via preparative TLC (2/1 acetone/hexanes, SiO_2) gave **8V** as a yellow oil (23 mg, 39%).

Preparation of 2,6-dimethyl-4-(4-pyridyl-N-oxide) benzoic acid



Step A: 4-Benzyl-2,6-dimethylbenzoic acid (8.7 g, 34 mmol; Thea, S. et al *Journal of the American Chemical Society* **1985**, 50, 1867), MeI (3.2 ml, 51 mmol), and Cs_2CO_3 (17 g, 51 mmol) were allowed to stir in DMF at 25 °C for 17 h. The solution was filtered and partitioned between Et_2O and water. The aqueous layer was extracted with Et_2O . The combined Et_2O layers were washed with H_2O and brine. The organic layer was dried (MgSO_4), filtered, and concentrated. Purification via flash chromatography (10/1 hexanes/ Et_2O , SiO_2) gave 8.6 g (94 %) of the methyl ester as a colorless oil.

Step B: The benzyl protected phenol (8.5 g, 32 mmol) and Pd/C (750 mg, 10 wt % Pd) were taken up in CH_3OH . The solution was charged with 50 psi H_2 and

shaken in a Parr apparatus at 25 °C for 17h. The solution was filtered (Celite). Concentration gave 5.6 g (98 %) of the phenol as a white solid.

Step C: The phenol (3.5 g, 19.4 mmol) and iPr₂NEt (3.76 g, 29.1 mmol) were dissolved in CH₂Cl₂ at 0 °C. Triflic anhydride (Tf₂O) (4.2 ml, 25.2 mmol) was

5 added dropwise to the solution at 0 °C. The solution was warmed to 25 °C and stirred at that temperature for 4.5 h. The solution was diluted with CH₂Cl₂ and washed with sat NaHCO₃. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried over Na₂SO₄. Filtration and concentration gave the crude aryl triflate. Purification via flash chromatography (10/1,

10 hexanes/Et₂O, SiO₂) gave 5.7 g (94 %) of the triflate as a yellow oil.

Step D: The triflate (1g, 3.2 mmol), 4-pyridyl boronic acid (1.2 g, 9.6 mmol), Pd(PPh₃)₄ (370 mg, 0.32 mmol), and Na₂CO₃ (1 g, 9.6 mmol) were taken up in DME/H₂O (4/1, 25 ml). The solution was heated to 90 °C (oil bath) under N₂ for 18 h. The solution was partitioned between EtOAc and H₂O. The aqueous layer 15 was extracted with EtOAc. The combined EtOAc layers were dried (Na₂SO₄). Filtration and concentration gave a dark brown oil. Purification via flash chromatography (3/1 hexanes/EtOAc, SiO₂) gave 770 mg (100 %) of the pyridyl derivative as an orange oil.

Step E: The pyridyl derivative (390 mg, 1.6 mmol) and mCPBA (550 mg, 3.2 mmol) were dissolved in CH₂Cl₂. The solution was stirred at 25 °C for 18 h. The solution was diluted with CH₂Cl₂ and washed with 1 N NaOH. The organic layer was dried (Na₂SO₄). Filtration and concentration gave 400 mg (97 %) of the N-oxide as an orange oil. HRMS (MH⁺) calcd. for C₁₅H₁₆O₃N, 258.1130; Found, 258.1131.


25 Step F: The methyl ester (400 mg, 1.6 mmol) was taken up in 5 ml of 3 N NaOH and 2 ml of EtOH. The solution was heated at reflux for 20 h. The solution was concentrated. The residue was treated with conc. HCl. The resulting solid was filtered and washed with water and brine. After drying under high vacuum, the free acid (377 mg, 100 %) was obtained as a tan solid. m.p. >225 °C (decomp).

30 HRMS (MH⁺) calcd. for C₁₄H₁₄O₃N, 244.0974; Found, 244.0981.

8W: The tri-hydrochloride salt of the product of Example 8, step 3 (1.34 g, 2.8 mmol), 2,6-dimethyl-4-formyl benzoic acid (500 mg, 2.8 mmol) (see preparation below), EDC (1.1 g, 5.6 mmol), HOBT (760 mg, 5.6 mmol) and iPrNEt (2 ml, 11 mmol) were subjected to the standard coupling conditions. Purification via flash

35 chromatography (2/1 hexanes/EtOAc, SiO₂) gave 898 mg (61 %) of **8W** as a yellow foam.

Preparation of 2,6-dimethyl-4-formyl benzoic acid



Step A: 4-Hydroxy-2,6-dimethylbenzoic acid, tert-butyl ester (6.4 g, 29 mmol) and iPr₂NEt (5.6 g, 43 mmol) were taken up in CH₂Cl₂ and cooled to 0 °C. Tf₂O

5 (5.8 ml, 34 mmol) was added slowly to the solution at 0 °C. The solution was stirred at 0 °C for 3 h. The solution was partitioned between sat. NaHCO₃ and CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄). Filtration and concentration gave a brown oil. Purification via flash chromatography (20/1 hexanes/Et₂O, SiO₂) gave 7.99 g (82

10 %) of the triflate as a yellow solid.

Step B: The triflate (5 g, 15 mmol), LiCl (1.25 g, 30 mmol), Pd(PPh₃)₄ (340 mg, 0.3 mmol), and vinyl tributyl tin (4.5 ml, 16 mmol) were taken up in THF under N₂. The solution was heated at 70 °C for 16 h. The solution was partitioned between EtOAc and sat. KF. The mixture was filtered. The organic layer was separated, 15 and the aqueous layers were extracted with EtOAc. The combined organic layers were dried (MgSO₄). Filtration and concentration gave a yellow oil. Purification via flash chromatography (20/1 hexanes/Et₂O, SiO₂) gave 1.96 g (57 %) of the olefin as a yellow oil.

Step C: The olefin (0.6 g, 2.6 mmol) was taken up in CH₂Cl₂/MeOH (1/1). The 20 solution was cooled to -78 °C. Ozone was bubbled through the solution until a dark blue color persisted. The reaction was quenched with dimethyl sulfide. The reaction was concentrated to furnish the aldehyde as an oil.


Step D: The tert-butyl ester (650 mg, 2.8 mmol) and TFA (3 ml) were taken up in CH₂Cl₂ and stirred at 25 °C for 19 h. Concentration of the solution gave the acid 25 as a beige solid.

8X: **8W** (100 mg, 0.19 mmol), H₂NOMe-HCl (28 mg, 0.34 mmol), NaOAc (32 mg, 0.46 mmol) were taken up in MeOH. The solution was stirred at 25 °C for 17h. The solution was concentrated. The residue was partitioned between CH₂Cl₂ and 1 N NaOH. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (Na₂SO₄). Filtration and concentration gave the crude product. Purification via preparative TLC (1/1 hexanes/EtOAc, SiO₂) gave 85 mg (84 %) of **8X**.

8Y: The tri-hydrochloride salt of the product of Example 8, step 3 (75 mg, 0.16 mmol) and 4-difluoromethyl-2,6-dimethyl benzoic acid (32 mg, 0.16 mmol) were subjected to the standard coupling conditions (EDC/HOBt/ iPr₂NEt). Purification via preparative TLC (2/1 hexanes/EtOAc, SiO₂) gave 64 mg (73 %) of **8Y**.

5

Preparation of 4-difluoromethyl-2,6-dimethyl benzoic acid




Step A: The aldehyde (400 mg, 1.7 mmol), [bis(2-methoxyethyl)amino]-sulfur trifluoride (640 mg, 2.9 mmol), and EtOH (0.02 ml, 0.34 mmol) were taken up 1,2-dichloroethane and stirred at 65 °C for 6 h and at 25 °C for 19 h. The solution was quenched with sat. NaHCO₃. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (NaSO₂). Filtration and concentration gave the crude product. Purification via preparative TLC (10/1 hexanes/Et₂O, SiO₂) gave 210 mg (50 %) of the difluoro derivative.

10 Step B: The tert-butyl ester (210 mg, 0.82 mmol) and HCl (2.1 ml of 4 M in dioxane, 8.2 mmol) were taken up in MeOH. The solution was stirred at 45 °C for 20 h. The solution was concentrated to obtain the acid as a white solid.

15 **8Z:** The tri-hydrochloride salt of the product of Example 8, step 3 (811 mg, 1.7 mmol) and 4-[(ethylamino)carbonylamino]-2,6-dimethyl benzoic acid (400 mg, 1.7 mmol) (see preparation below) were subjected to the standard coupling conditions (EDC/HOBt/iPr₂NEt). Purification via flash chromatography (1/1 hexanes/acetone, SiO₂) gave 803 mg (81 %) of **8Z** as a foam.

Preparation of 4-[(ethylamino)carbonylamino]-2,6-dimethyl benzoic acid



Step A: 3,5-Dimethyl aniline (18.5 ml, 149 mmol) was taken up in CH₂Cl₂. The

25 solution was cooled in a water bath. Trifluoroacetic anhydride (29.5 ml, 209

mmol) was added slowly to the solution. After the addition, the solution was stirred at 25 °C for 15 minutes. Bromine (7.3 ml, 142 mmol) was added slowly to the solution while maintaining the RT water bath. The solution was stirred at 25 °C for 3.5 h. The solution was quenched with 10% Na₂S₂O₃. The aqueous layer 5 was extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄), treated with activated carbon and filtered. Concentration gave an orange solid. Purification via recrystallization (hexanes/Et₂O) gave two crops (34 g total, 77%) of the brominated derivative as a white solid.

Step B: The aryl bromide (17 g, 57 mmol) was taken up in THF and cooled to – 10 78 °C under N₂. Methylolithium/LiBr (54 ml of a 1.5 M solution in Et₂O, 80 mmol) was added slowly to the solution at –78 °C. After 5 min of stirring, sec-BuLi (62 ml of a 1.3 M in cyclohexane, 80 mmol) was added slowly to the reaction solution at –78 °C. After 5 min, di-t-butyl dicarbonate (22.5g, 103 mmol) in THF was added to the solution at –78 °C. The solution was warmed to 25 °C. After 30 15 min, the reaction mixture was partitioned between water and CH₂Cl₂. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were dried (MgSO₄). Filtration and concentration gave a yellow solid. Purification via flash chromatography (1/1 to 1/4 hexanes/CH₂Cl₂, SiO₂) gave 13.1 g (72 %) of the tert-butyl ester as an off-white solid.

Step C: The trifluoro-acetamide (10 g, 31 mmol) and NaOH (2.5 g, 62 mmol) 20 were taken up in MeOH/H₂O (3/1) and heated at 60 °C for 3 h. The solution was partitioned between CH₂Cl₂ and water. The aqueous layer was extracted with CH₂Cl₂. The combined organic layers were washed with water and dried (Na₂SO₄). Filtration and concentration gave 6.4 g (93 %) of the aniline as an 25 orange solid.

Step D: The aniline (1 g, 4.5 mmol), ethyl isocyanate (0.4 ml, 5 mmol), and CuCl (90 mg, 0.9 mmol) were taken up in DMF at 0 °C. The solution was warmed to 25 °C and stirred at that temperature for 2h. The solution was partitioned between EtOAc and 10 % NH₄OH. The aqueous layer was extracted with EtOAc. The 30 combined layers were washed with brine and dried (MgSO₄). Filtration and concentration gave a yellow solid. Purification via flash chromatography (3/1 to 1/1 hexanes/EtOAc, SiO₂) gave 904 mg (69 %) of the urea as a yellow solid.


Step E: The tert-butyl ester (900 mg, 3.1 mmol) and 4 M HCl in dioxane (3 ml) 35 were taken up in iPrOH and heated at 45 °C for 3.5 h and at 25 °C for 16.5 h. The solution was concentrated under reduced pressure. The residue was partitioned between Et₂O and 1 N NaOH. The aqueous, basic layer was extracted with Et₂O. The aqueous layer was cooled to 0 °C and acidified with conc. HCl (pH = 1-2). The aqueous layer was extracted with EtOAc. The

combined EtOAc layers were dried (Na_2SO_4). Filtration and concentration gave the 400 mg (55 %) of the acid as a white solid.

8AA: The tri-hydrochloride salt of the product of Example 8, step 3 (2 g, 4.3 mmol) and 4-amino-2,6-dimethyl benzoic acid (710 mg, 4.3 mmol) (see

5 preparation below) were subjected to the standard coupling conditions (EDC/HOBt/iPr₂NEt). Purification via flash chromatography (2/1 hexanes/acetone, SiO_2) gave 1.16 g (52 %) of **8AA** as a yellow foam.

Preparation of 4-amino-2,6-dimethyl benzoic acid




10 The tert-butyl ester (950 mg, 4.3 mmol) and HCl (11 ml, 4 M in dioxane) were taken up in MeOH at heated at 45 °C for 20 h. The solution was concentrated to obtain the acid (710 mg) in quantitative yield.

8BB: **8AA** (100 mg, 0.19 mmol) and ethane sulfonyl chloride (0.02 ml, 0.21 mmol) were taken up in pyridine and stirred at 25 °C for 19 h. The solution was

15 concentrated. The residue was partitioned between 1 N NaOH and CH_2Cl_2 . The aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4). Filtration and concentration gave a brown oil. Purification via preparative TLC (2/1 hexanes/acetone, SiO_2) gave 100 mg (86 %) of **8BB** as a colorless oil.

20 **8CC:** The trihydrochloride salt of the product of Example 8, step 3 (127 mg, 0.27 mmol) and 4-fluoro-2,6-dimethyl benzoic acid (58 mg, 0.35 mmol) (see preparation below) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (2/1 hexanes/ EtOAc, SiO_2) gave **8CC** as a colorless oil (87 mg bis-HCl salt, 54 %).


Preparation of 4-fluoro-2,6-dimethyl benzoic acid



25 4-Amino-2,6-dimethyl benzoic acid (200 mg, 1.1 mmol) and NOBF_4 (196 mg, 1.7 mmol) were heated in 1,2-dichlorobenzene at 100 °C for 30 min. The solution was cooled and diluted with MeOH and water. A few pellets (2-3) of KOH were added, and the solution was heated at reflux for 16 h. The solution was concentrated. The residue was partitioned between Et_2O and 1 N NaOH. The aqueous layer was extracted with Et_2O . The aqueous layer was cooled to 0 °C and acidified with conc. HCl (pH = 1-2). The aqueous layer was extracted with CH_2Cl_2 . The organic layers were



dried (Na_2SO_4). Filtration and concentration gave 58 mg (31 %) of the acid as a tan solid.

8DD: The trihydrochloride salt of the product of Example 8, step 3 (150 mg, 0.31 mmol) and 4-chloro-2,6-dimethyl benzoic acid (76 mg, 0.41 mmol) (see preparation below) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (4/1 hexanes/ acetone, SiO_2) gave **8DD** as a colorless oil.



10 4-Amino-2,6-dimethyl benzoic acid (172 mg, 0.96 mmol) and CuCl_2 (155 mg, 1.15 mmol) were taken up in CH_3CN at 0 °C. Tert-butyl nitrite (0.17 ml, 1.4 mmol) was added to the solution at 0 °C. The solution was warmed to 25 °C and then at 65 °C for 45 min. The solution was partitioned between Et_2O and water. The aqueous layer was extracted with Et_2O . The combined organic layers were washed with brine and dried (MgSO_4). Filtration and concentration gave the methyl ester. The methyl ester was hydrolyzed as described above for the fluoro derivative (KOH). After extractive workup, 4-chloro-2,6-dimethyl benzoic acid (158 mg, 89 %) was obtained as a yellow solid.

15 **8EE:** The trihydrochloride salt of the product of Example 8, step 3 (180 mg, 0.38 mmol) and 4-bromo-2,6-dimethyl benzoic acid (95 mg, 0.41 mmol) (see preparation below) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (4/1 hexanes/ acetone, SiO_2) gave **8EE** as a colorless oil (140 mg bis-HCl salt, 56 %).




25 Step A: The triflate (500 mg, 1.48 mmol), hexamethylditin (0.31 mmol, 1.48 mmol), LiCl (377 mg, 8.9 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (171 mg, 0.15 mmol) were heated in THF (70 °C) under N_2 for 21 h. The solution was partitioned between Et_2O and pH = 7 buffer (NH_4OAc). The aqueous layer was extracted with Et_2O . The combined Et_2O layers were washed with brine and dried (Na_2SO_4). Filtration and concentration gave the crude aryl stannane as a yellow semisolid.

30 Step B: The aryl stannane (0.74 mmol) was taken up in CH_2Cl_2 at 0 °C. Bromine (0.7 ml of 1 M Br_2 in CH_2Cl_2) was added to the solution. The solution was stirred at 0 °C for 30 min. The solution was diluted with CH_2Cl_2 and washed with 10 % $\text{Na}_2\text{S}_2\text{O}_3$. The aqueous layer was extracted with CH_2Cl_2 . The combined organic

layers were dried (Na_2SO_4). The solution was filtered. TFA (2 ml) was added to the solution, and the solution was stirred at 25 °C for 17 h. The solution was concentrated. The residue was partitioned between Et_2O and 1 N NaOH. The aqueous layer was extracted with Et_2O . The aqueous layer was cooled to 0 °C and acidified with conc. HCl (pH = 1-2). The aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4). Filtration and concentration gave 100 mg (59 %) of the acid as a white solid.

Using procedures described following the table, compounds 8FF-8HH of the structure



10


were prepared, wherein R^{11} is defined in the table:

Ex.	R^{11}	Mp (°C)	HRMS (MH^+)
8FF	-OCH ₃	217-220 (2xHCl salt)	572.2048
8GG	-OH	198-204 (2xHCl salt)	558.1898
8HH		200-205 (2xHCl salt)	635.2172

15 **8FF:** The trihydrochloride salt of the product of Example 8, step 3 (100 mg, 0.21 mmol) and 2,6-dichloro-4-methoxy-benzoic acid (140 mg, 0.63 mmol) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (3/1 hexanes/EtOAc, SiO_2) gave **8FF** as a colorless oil (27 mg, 23 %).

20 **8GG:** The trihydrochloride salt of the product of Example 8, step 3 (330mg, 0.7 mmol) and 2,6-dichloro-4-hydroxy-benzoic acid (290 mg, 1.4 mmol) (see preparation below) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (1/1 hexanes/ EtOAc, SiO_2) gave **8GG** as a colorless oil (75 mg, 19 %).

Preparation of 2,6-dichloro-4-hydroxy-benzoic acid




25 2,6-Dichloro-4-methoxy-benzoic acid (500 mg, 2.3 mmol) was taken up in CH_2Cl_2 and cooled to -78 °C. BBr₃ (6.9 ml of a 1 M solution in CH_2Cl_2) was added to the solution at -78 °C. The solution was warmed to 25 °C and stirred at that temperature for 16 h. The solution was quenched with 3 N NaOH. The

aqueous layer was extracted with CH_2Cl_2 . The aqueous layer was cooled ($0\text{ }^\circ\text{C}$) and acidified with conc. HCl (pH = 1-2). The aqueous layer was extracted with CH_2Cl_2 . The combined organic layers were dried (Na_2SO_4). Filtration and concentration gave the crude phenol which was used without further purification.

5 **8HH:** The trihydrochloride salt of the product of Example 8, step 3 (96 mg, 0.2 mmol) and 2,6-dichloro-4-(4-pyridyl-N-oxide)-benzoic acid (55 mg, 0.2 mmol) (see preparation below) were coupled according to the general procedure (EDC/HOBt/iPr₂NEt). Purification via preparative TLC (1/5 hexanes/acetone, SiO₂) gave **8HH** as a colorless oil (54 mg, 43 %).


10 Preparation of 2,6-dichloro-4-(4-pyridyl-N-oxide) benzoic acid



2,4,6-Trichloro benzoic acid, tert-butyl ester (500 mg, 1.8 mmol), 4-pyridyl boronic acid (270 mg, 2.16 mmol), $\text{Pd}(\text{PCy}_3)_2\text{Cl}_2$ (130 mg, 0.18 mmol), and CsF (540 mg, 3.6 mmol) were taken up in NMP and heated at 100 °C under N_2 (16 h).











15 The solution was partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and brine and dried (Na_2SO_4). Filtration and concentration gave the crude product. Purification via preparative TLC (1/1 hexanes/EtOAc, SiO_2) gave 68 mg (12 %) of the pyridyl ester. The tert-butyl ester was converted into the acid as done
20 previously for the dimethyl derivative (a. mCPBA /b. TFA).

Using suitable starting materials and the procedures described for examples 8S to 8HH, the compounds of the following structure were prepared:



wherein R^{11} is defined in the table

Ex.	R ¹¹	m.p. (°C)	HRMS (MH ⁺) calc.	HRMS (MH ⁺) found
8II	-OCH ₃	236-240	532.3151	532.3166
8JJ	-CH ₃	> 260	516.3202	516.3213
8KK		186-190	603.3522	603.3513


8LL		202-208	579.3311	579.3303
8MM		210-216	579.3311	579.3311
8NN		196-203	595.3260	595.3256
8OO		> 230 (dec)	578.3358	578.3368
8PP		135-140	617.3679	617.3671
8QQ		205-215	602.3682	602.3722
8RR	CH ₂ OH	> 235 (dec)	532.3151	532.3124
8SS		206-212	580.3263	580.3258
8TT		198-204	579.3311	579.3315
8UU		231-236	580.3263	580.3252
8VV		201-207	613.2977	613.2981
8WW		215-220	650.2487	650.2497
8XX		198-201	545.3103	545.3098
8YY		210-214	595.2930	595.2921
8ZZ	CH ₂ F	> 245	534.3108	534.3117
8AB		202-205	624.3195	624.3204
8AC		208-213	559.3260	559.3263
8AD		215-220	560.3212	560.3220

8AE		215-220	573.3416	573.3424
8AF		215-220	559.3260	559.3257
8AG		205-209	602.3682	602.3672
8AH		186-192	574.3369	574.3378
8AI		200-206	616.3838	616.3844
8AJ		165-173	661.3941	661.3949
8AK	CN	240-250	527.2998	527.2991
8AL		211-215	622.3136	622.3129
8AM		170-174	616.3838	616.3836
8AN		192-196	614.3682	614.3690

All melting points were done on the bis hydrochloride salts (2xHCl) except 8PP was performed on the free base

Using derivatives of the triflate intermediate described in 8Z in procedures similar to those described above and following the table for 8AO-8AQ, the


5 compounds of the following structure were prepared:



wherein R¹¹ is defined in the table

Ex.	R ¹¹	m.p. (°C)
8AO	-CN	240-250
8AP	-CONHEt	215-220
8AQ	-N(CH ₃)CONHEt	186-203
8AR	-CONH ₂	200-208
8AS	-CONHCH ₃	215-220

8AT	-CON(CH ₂ CH ₂ OCH ₃) ₂	165-173
8AU	-CON(Et) ₂	170-180
8AV	-N(CH ₃)CONHCH ₃	198-210
8AW	-NHCH ₃	190-200
8AX	-N(CH ₃)CONH ₂	190-220


8AO:

Step 1: The triflate intermediate (see 8W) (0.4 g), Zn(CN)₂ (0.2 g), Pd(PPh₃)₄ (0.3 g) and DMF (1.5 ml) were heated at 80 °C for 17 h. The reaction was cooled to

5 RT, diluted with EtOAc and saturated aqueous NaHCO₃. The EtOAc layer was removed, washed with water, dried with brine and evaporated to give a crude oil which was purified by preparative plate chromatography (2000 µM silica plates; 8:1 hexanes: EtOAc eluant), to give, after isolation of the appropriate band, the cyano intermediate (0.2 g) in 77% yield.

10 Step 2: The product of Step 1 (0.2 g) was dissolved in MeOH (1.5 ml) and HCl (4M solution in 1,4-dioxane; 2 ml) was added. The resulting solution was stirred at 50 °C for 3 h and evaporated. This crude intermediate (0.038 g) and the product of Example 8, Step 3 (65 mg; trihydrochloride form) were treated in the same fashion as Example 8, Step 4, using DMF (2 ml), HOEt (45 mg), DEC (60 mg) and diisopropyl ethyl amine (0.1 ml) to give, after isolation and purification, the free base form of 8AO, which was converted to its HCl salt (45 mg) in 95% yield.

15

8AP:

20 Step 1: 2,6-Dimethyl-4-formyl benzoic acid (1.96 g) (see 8W) was dissolved in t-butanol (94 ml) and 2-methyl-2-butene (24 ml). A solution of NaClO₂ (6.89 g), NaH₂PO₄ monohydrate (8.17 g) and water (45 ml) was added dropwise to the first solution. After complete addition, the pH was adjusted to 3 and two layers resulted. The organic layer was removed and evaporated to give intermediate acid (1.80 g) as a white crystalline solid, which was used without purification.

25 Step 2: To a solution of the product of Step 1 (0.62 g), CH₂Cl₂ (5 ml) and DMF (1 drop) was added oxalyl chloride (0.31 ml) and the resulting solution was stirred for


10 min, at which time a second portion of oxalyl chloride (0.30 ml) was added.

The reaction was stirred for 10 min, toluene was added and the mixture was evaporated to dryness. CH_2Cl_2 (10 ml) and EtNH_2 (1 ml) were added and the reaction was stirred for 2 days, then partitioned between brine and CH_2Cl_2 . The

5 CH_2Cl_2 layer was evaporated and HCl (4 ml of a 4 M solution in 1,4-dioxane) was added. The resulting solution was stirred for 3 h and evaporated to give a solid which was washed with Et_2O and collected to give the amide intermediate (0.13 g) in 24 % yield.

10 Step 3: The product of Example 8, Step 3 (60 mg; trihydrochloride form) and the product of step 2 (35 mg) were treated in the same fashion as Example 8, Step 4 to give, after work up and purification, **8AP** as the free base form, which was converted to the HCl salt (50 mg) in 62% yield.

8AQ:




15 Step 1: To a solution of the amine intermediate (2 g) (see **8Z**) was added NaH (0.4 g of a 60% oil dispersion). The resulting suspension was stirred for 15 min and Me_2SO_4 was added. After heating at reflux for 1.5 h, the reaction was cooled to RT, poured into saturated NH_4Cl aqueous solution and extracted with Et_2O . After evaporation, the crude reaction mixture was chromatographed on silica gel, 20 eluting with 4:1 hexanes: EtOAc , to give, after evaporation of the appropriate fractions, the methylamine intermediate (0.8 g) in 38% yield.

25 Step 2: The product of Step 1 (0.12 g), THF (5 ml) and EtNCO (54 mg) were heated at reflux for 17 h. EtNCO (54 mg) and 1,4-dioxane (2 ml) were added and the resulting solution was heated in a sealed tube at 65 °C for 17 h. The solution was cooled, evaporated and purified by preparative plate chromatography (silica gel; 25% $\text{EtOAc}:\text{CH}_2\text{Cl}_2$), to give the desired product (0.1 g) as a crystalline solid in 64% yield.

30 Step 3: The product of Step 2 (0.1 g) was treated in the same fashion as Example 8, Step 3 (p 28) to give the desired intermediate (0.08 g) which was used directly in the next step.

35 Step 4: The product of Example 8, Step 3 (75 mg; trihydrochloride form) and the product of Step 3 (0.04 g) were treated in the same fashion as Example 8, Step 4, to give, after work up and purification, **8AQ** as the free base form, which was converted to the HCl salt (65 mg) in 62% yield.


Using procedures described above and employing commercially available acids, compounds **8AY-8BT** of the structure



were prepared, wherein R¹⁰ and R¹¹ are defined in the table:

Ex.	R ¹⁰	R ¹¹	Mp (°C)
8AY	-CH ₃	H	205-208
8AZ	F	H	250-255
8BA	Cl	H	215-217
8BC	-CH ₃	Br	228-231
8BD	-CH ₃		194-198
8BE	Cl	Cl	240-241
8BF	Cl	F	268-270
8BG	Br	H	210-213
8BH	Cl	Br	213-217
8BI	Br	F	176-181
8BJ	I	H	184-190
8BK	-CF ₃	F	204-209
8BL	F	F	268-270
8BM	Cl	NH ₂	215-220
8BN	H	F	258-260
8BO	H	Br	238-240
8BP	H	Cl	235-240
8BQ	Br	Cl	190-194
8BR	CH ₃ CH ₂ -	H	211-214
8BS	-Si(CH ₃) ₃	H	230-240
8BT	Cl	NO ₂	275-280













Using procedures similar to those described above, the following compounds were prepared:




5

wherein R⁸, R³, R⁶ and R² are as defined in the table:

Ex.	R ⁸	R ³	R ⁶	R ²	Mp (°C)

8BU	-CF ₃		-CH ₃		195-220
8BV	-CF ₃		-CH ₃		80-85
8BW	-CF ₃		-CH ₃		212-217
8BX	-CF ₃		-CH ₃		235-238
8BY	-CF ₃		-CH ₃		195-200
8BZ	-CF ₃		-CH ₃		237-240
8CA	-CF ₃		-CH ₂ CH ₃		179-181
8CB	-CF ₃		-CH ₂ CH ₃		200-202
8CD	-CF ₃		-CH ₂ CH ₃		199-205
8CE			-CH ₃		206-210
8CF	-CF ₃		-CH ₃		235-239

Example 9



5 Step 1: A solution of 4-N-BOC-2(S)-methyl piperazine (1.5g; 7.5 mmol), 4-methoxy-benzyl chloride (1.1 ml; 8.1 mmol) and diisopropyl ethyl amine (1.5 ml) in dry CH_3CN were heated at reflux for 5 h. The reaction mixture was cooled to RT and volatiles were removed in vacuo. The residue was dissolved in CH_2Cl_2 (30 ml) and washed with water and brine. Concentration gave the crude product,

which was purified by FSGC (10% EtOAc-hexanes) to obtain 2.1g (88%) of product as a pale yellow liquid.

TFA (6 ml) was added to a solution of the above compound (2.1g; 6.56 mmol) in 12 ml of CH_2Cl_2 and the mixture stirred at 25° C for 1.5 h. The reaction

5 was quenched with 1N NaOH and adjusted to pH 10. Extractive work-up in CH_2Cl_2 furnished the desired product (1.4g; 97%) as a colorless gum.

Step 2: A mixture of the product of step 1 (1.4g; 6.36 mmol), N-BOC-4-piperidinone (1.27g; 6.4 mmol) and $\text{Ti}(\text{O}i\text{Pr})_4$ (1.9 ml; 6.4 mmol) was stirred at 25° C for 24h. A 1M solution of Et_2AlCN in toluene (7.6 ml) was added to the reaction mixture and the mixture stirred at ambient temperature for another day. The Strecker amine thus formed was worked-up and isolated (2.7g; 100%) as described in Example 8, step 2. TLC R_f = 0.3 in 25% EtOAc- CH_2Cl_2 .

The Strecker amine (2.7g; 6.3 mmol) was dissolved in 15 ml of dry THF at 0° C and CH_3MgBr (3M in Et_2O ; 10.5 ml) was added to it. After 1 h, the ice bath

15 was removed and the reaction allowed to proceed at RT for 15 h. TLC analysis of the heterogeneous reaction mixture showed no change from the starting material; the mixture was warmed at 60° C for 5 h with no observed change in TLC behavior. The reaction mixture was quenched with saturated NH_4Cl and organic products extracted into CH_2Cl_2 . FSGC of the crude 20 product (2.7g) using 15% acetone-hexanes as the eluant provided the desired ipso-methyl compound as a colorless gum (2.3g; 87%).

Step 3: The product of step 2 (1.7g; 4.08 mmol), ammonium formate (1.4g; 22 mmol) and 10% palladium on carbon (0.4g) were mixed in 20 ml of CH_3OH and heated at reflux for 5 h. The reaction mixture was filtered through celite and 25 volatiles were removed. The residue was dissolved in CH_2Cl_2 and washed with 10% NaOH solution, water and brine. Concentration in vacuo gave 1.1g (92%) of pale yellow gum.

Step 4: A solution of the product of step 3 (0.12g; 0.4 mmol), p-trifluoro-methyl benzyl bromide (0.1g; 0.4 mmol) and diisopropyl ethyl amine (0.1 ml) in dry 30 CH_3CN was gently warmed (60-70° C) for 16 h. The mixture was cooled and organic product isolated via extractive work-up in CH_2Cl_2 . FSGC (10-30% Et_2O - CH_2Cl_2 ; R_f = 0.4) yielded the major product as a colorless film (0.12g; 68%).


Treatment of the above product (in CH_2Cl_2) with TFA (1 ml) for 1 h followed by basification and standard work-up provided the desired compound 35 (0.09g; 96%) as a colorless film.

Step 5: The product of step 4 (0.045g; 0.13 mmol) and 6-chloro anthranilic acid (0.022g; 0.13 mmol) were coupled as described in Example 1 and after work-up

and FSGC (5% CH_3OH in CH_2Cl_2) the title compound was isolated as a colorless film (0.058g; 90%).

The HCl salt of the title compound was prepared in the usual manner by the reaction of the free base with 1M HCl- Et_2O and processing the precipitate to 5 obtain a beige solid (0.066g).








Using a similar procedure, the product of step 3 was converted to other compounds, first by alkylation of the piperazine nitrogen with the appropriate halide, followed by deprotection and coupling of the piperidinyl portion with the appropriate acid to form the amides of general structure:



10

wherein R and R^2 are as defined in the table:

Ex.	R	R^2	Mp (°C)	HRMS (MH^+)
9A			246-249	509.2293
9B			204-208	488.2895
9C			247-249	546.1978
9D			249-251	567.1407
9E			206-209	504.2848
9F			244-247	525.2242
9G			201-204	484.2630
9H			222-226	505.2039

9I			226-229	451.3060
9J			229-232	472.2474
9K			268-271	455.2577
9L			212-216	476.1975
9M			229-232	450.3126
9N			246-251	434.3168
9O			192-205	--
9P			185-196	--
9Q			202-210	--
9R			203-206	--
9S			190-205	--
9T			180-205	--
9U			258-262	--


Using a similar procedure described below, compounds wherein R is 4-ethoxynaphthyl were also prepared:

Steps 1-3: See Example 9.


Step 4A: 4-Hydroxynaphthaldehyde (0.86g) and K_2CO_3 (1.38g, 2 equiv.) in CH_3CN (35 ml) were treated with CH_3CH_2I (0.80 ml, 2 equiv.), and the resulting mixture was stirred at RT for 20 h. The reaction mixture was concentrated in vacuo, the residue treated with $EtOAc$, and the mixture filtered. The filtrate was partitioned with H_2O . The dried ($MgSO_4$) $EtOAc$ was concentrated in vacuo to give an orange-brown residue (0.89g). This residue was placed on preparative thin layer plates (10, 1000 μ), and eluted with CH_2Cl_2 to give the title compound (0.82g).

Step 4: Under argon, the products of step 3 (0.270g; 0.95 mmol) and step 4A (0.571g; 2.9 mmol) in CH_2Cl_2 (25 ml) were stirred at RT for 30 min. $Na(OAc)_3BH$ (0.506g; 3.4 mmol) was added. After 19 h, the reaction mixture was quenched with dilute $NaOH$. The aqueous layer was washed with CH_2Cl_2 (3X). The combined CH_2Cl_2 solution was washed with H_2O (3X) and then brine. The dried ($MgSO_4$) CH_2Cl_2 solution was concentrated to ~50 ml. Amberlyst 15 (4.5 meq/g: 15 2.4g; 11.025 mmeq) was added. After 19 h, additional Amberlyst 15 (2.3g) was added. After 7 h, the resin was washed with CH_2Cl_2 (5X), THF (5X), $THF:H_2O$ (5X), H_2O (5X), CH_3OH (5X) and CH_2Cl_2 (5X). The resin was eluted with 2M NH_3 in CH_3OH (300 ml) (3X), followed by concentration in vacuo to give an amber oil (0.215g). The crude material was placed on preparative thin layer plates (4, 20 1000 μ), and eluted with $CH_2Cl_2:2M\ NH_3$ in CH_3OH (9:1) to give an amber oil (0.125g, 36%).

Step 5: Using the appropriate carboxylic acid in the procedure of Example 9, step 5, the following compounds were prepared:




25 LCMS found $M^+H = 531$; HPLC* Retention time 5.52 min.



LCMS found $M^+H = 516$; HPLC* Retention time 5.66 min.


*HPLC: VYDAC 218TP5405 column; gradient 5-95% B over 10 min hold 2 min; Soln A 0.1% TFA/ H_2O , Soln B 0.1% TFA/ CH_3CN at 245 nm.

Using a similar procedure wherein the starting piperazine does not have the methyl substituent, the following compound was prepared:



5

Example 10



- A. $R^9 = NH_2$; $R^{10} = Cl$
- B. $R^9 = NH_2$; $R^{10} = CH_3$
- C. $R^9, R^{10} = CH_3, CH_3$

Step 1: A solution of 4-N-BOC-2(S)-methyl piperazine (0.4g; 2 mmol), p-iodobenzaldehyde (0.46g; 2 mmol) and $NaBH(OAc)_3$ (0.65g; 3 mmol) in 6 ml of CH_2Cl_2 was heated at gentle reflux for 14 h. The contents were cooled, diluted with 30 ml of CH_2Cl_2 and washed with 1N NaOH solution, water and brine to isolate an yellow oil (0.8g). FSGC (25% EtOAc-hexane) afforded the desired product (0.66g; 79%) as a colorless film. $TLC R_f = 0.6$ in 25% EtOAc-hexane

The BOC protecting group was removed from the product (0.66g; 1.58 mmol) by treatment with TFA (1 ml) in CH_2Cl_2 (2 ml). Following standard work up, the mono-alkylated piperazine (0.5g; 100%) was obtained as a colorless gum.

Step 2: $NaBH(OAc)_3$ (0.63g; 3 mmol) and two drops of AcOH were added to a solution of the product of step 1 (0.5g; 1.58 mmol) and N-BOC-piperidinone (0.6g; 3 mmol) in 5 ml of CH_2Cl_2 and the resulting solution was stirred at ambient temperature for 16 h. After the usual work up and FSGC, the desired product (0.6g; 76%) was obtained as a colorless oil. $TLC R_f = 0.4$ in 25% acetone- CH_2Cl_2 .

The free piperidine (0.38g; 79%) was prepared from the N-BOC protected compound (0.6g; 1.2 mmol) by treatment with TFA (2 ml) in CH_2Cl_2 (5 ml).

Compound 10A: The coupling of 6-chloro anthranilic acid (0.065g; 0.38 mmol) with the product of step 2 (0.127g; 0.32 mmol) in the presence of DEC (0.092g; 0.48 mmol), HOBT (0.065g; 0.48 mmol) and diisopropylethyl amine (0.1 ml), followed by product isolation, were carried out as described previously. This procedure furnished the compound 10A (0.13g; 73%) as a colorless film. $TLC R_f = 0.5 / 0.45$ for a pair of rotomers in 2% $CH_3OH-CH_2Cl_2$.

The HCl salt of the title compound was prepared in the usual manner. Mp: 198-202° C; HRMS (MH⁺) = 553.1231.


Compound 10B: Coupling the product of step 2 with 6-methyl anthranilic acid gave compound 10B (HCl salt) in 73% yield. Mp: 197-200° C; HRMS (MH⁺) =

5 533.1774.

Compound 10C: 2,6-Dimethyl benzoic acid was coupled to the product of step 2 to obtain the amide 10C (HCl salt) in 50% yield. Mp: 202-205° C; HRMS (MH⁺) = 532.1826.

Example 11

10



Step 1: (S)-Methylbenzylamine (27 ml, 0.2 mol) in CH₂Cl₂ (50 ml) was dropped into ice-cold trifluoroacetic anhydride (40 ml) in CH₂Cl₂ (200 ml) within 15 min.

The mixture was stirred at RT for 1 h, then cooled in an ice water bath, iodine was

15 added (27 g, 0.106 mol) and then [bis(trifluoro-acetoxy)iodo]-benzene (25 g, 0.058 mol). After being stirred at RT overnight in the dark, more

[bis(trifluoroacetoxy)iodo]benzene (24 g, 0.056 mol) was added and the mixture was stirred at RT for one more day. The mixture was diluted with CH₂Cl₂ (500 ml) and ice-cold Na₂SO₃ (10% aqueous, 500 ml) and stirred for 0.5 h. The

20 organic layer was separated and washed with NaHCO₃, filtered through a short silica gel column and washed with CH₂Cl₂ (500 ml). After CH₂Cl₂ was evaporated, Et₂O (125 ml) was added and the mixture stirred for 10 min.

Hexanes (600 ml) was added gradually to the Et₂O solution and the mixture was stirred for 0.5 h. The precipitate was collected and washed with hexanes. The

25 white solid was dried at RT and iodo compound (36.5 g, 53% yield, R_f = 0.7, EtOAc/hexanes, 1:3) was obtained.

Step 2: The product of step 1 (11.2 g, 0.033 mol) was dissolved in CH₃OH (200 ml) and NaOH (15 g, 0.375 mol) in water (100 ml) was added dropwise. The mixture was stirred at RT for 2.5 h. After the CH₃OH was evaporated, the

30 aqueous layer was extracted with Et₂O (3x100 ml) and the combined organic portion was washed with brine, dried over Na₂SO₄, filtered and concentrated to give a free amine.

Methyl-*R*-lactate (4.08 g, 0.039 mol) was dissolved in CH₂Cl₂ (40 ml) and the mixture was stirred and cooled in acetone-CO₂ to -78° C under N₂

35 atmosphere. Trifluoromethane sulfonic anhydride (10.2 g, 0.036 mmol) and then 2,6-lutidine (6.27 g, 0.059 mol) were added and the mixture was stirred for 5 min

at -78° C. The mixture was warmed to RT and stirred for 30 min. More CH₂Cl₂ was added to the mixture and the solution was washed with 2N HCl. The freshly prepared amine from above was added to the triflate solution followed by K₂CO₃ (18 g, 0.132 mol) in water (20 ml). The mixture was stirred at RT overnight.

5 Extractive work-up with CH₂Cl₂ followed by silica gel column chromatography gave a secondary amine (8.27 g, 75% yield, R_f = 0.65, hexanes/EtOAc, 3:1) as a yellow syrup.

Step 3: The amine of step 2 (17.3 g, 0.052 mol) was dissolved in dichloroethane (100 ml) and ClCH₂COCl (117.2 g, 82 ml, 1.04 mol). The mixture was stirred under reflux condition for 3 h. Both the solvent and ClCH₂COCl were removed under vacuum. The remaining yellow syrup was dissolved in DMSO (40 ml) at 0° C and NaI (5.2 g, 0.035 mol) and NH₄OH (56 ml, 1.04 mol) were added. The reaction mixture was stirred 0° C for 30 min., warmed up to RT and stirred overnight. Water (100 ml) was added to the mixture and the precipitate was

10 filtered and washed with water. The white solid obtained was dried in air to give the diketopiperazine (14.3 g, 77% yield, R_f = 0.56, hexanes/ EtOAc, 3:1).

Step 4: The diketopiperazine of step 3 (14.3 g, 0.04 mol) was dissolved in dimethoxy ethane (200 ml) and NaBH₄ (15.1 g, 0.4 mol) and BF₃·OEt₂ (34 g, 29.5 ml, 0.24 mol) were added to the solution. The mixture was stirred under reflux conditions for 3 h and then cooled to about 0° C on a ice bath. CH₃OH (500 ml) and then concentrated HCl (300 ml) were added slowly to the mixture. The solution was stirred for 20 min. at RT and then under reflux conditions for 45 min. The mixture was concentrated and NaOH was added until the pH was more than 10. Extractive work up with EtOAc gave the desired piperazine as a yellow syrup (12.9 g, 98% yield).


Step 5: The product of step 4 (1.9 g, 5.79 mmol) , N-BOC-4-piperidone (5.73 g, 28.8 mmol), NaBH(OAc)₃ (6.1 g, 28.8 mmol) and 2M AcOH (5.76 ml, 11.52 mmol) were combined in CH₂Cl₂ (150 ml) and the mixture was stirred overnight.

After the solvent was removed, NaOH (3N) was added and extractive work up with EtOAc followed by silica gel chromatography afforded pure piperazino-piperidine (2.21 g, 75% yield, R_f = 0.18, hexanes/EtOAc, 1:1) as a syrup.

Step 6: The product of step 5 (1.9 g, 3.7 mmol) was dissolved in CH₂Cl₂ (10 ml) and TFA (10 ml) was added. The mixture was stirred at RT for 2 h. After the removal of the solvent and TFA under reduced pressure, NaOH solution (3N) was added to the remaining syrup and extractive work up with EtOAc gave the free piperazino-piperidine (1.3 g, 85% yield) as a yellow syrup. To a solution of the free piperazino-piperidine (200 mg, 0.484 mmol) in CH₂Cl₂ (2 ml) were added

2,6-dimethylbenzoic acid (150 mg, 0.99 mmol), DEC (191 mg, 0.99 mmol) and HOBT (135 mg, 0.99 mmol). The mixture was stirred at RT overnight and then the solvent was removed under reduced pressure. NaOH solution (3N) was added to the remaining syrup and extractive work up with EtOAc followed by 5 column chromatography afforded the title compound (210 mg, 80% yield, $R_f = 0.37$, $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$, 20:1). HRMS (as the HCl) calcd for $\text{C}_{27}\text{H}_{37}\text{N}_3\text{O}_1$ ($\text{M}+\text{H}^+$) 546.1981, found 546.1965. Mp: 190° C (dec.).


Using a similar procedure, compounds of the formula



10 were prepared, wherein R^9 and R^{10} are as defined in the table:

Ex	R^9	R^{10}	Mp (°C)	HRMS
11A	$-\text{CH}_3$	$-\text{NH}_2$	198 (dec.)	547.1928
11B	$-\text{Cl}$	$-\text{NH}_2$	203 (dec.)	567.1395
11C	$-\text{OH}$	$-\text{OH}$	200 (dec.)	550.1555
11D	$-\text{OCH}_3$	$-\text{OCH}_3$	200 (dec.)	578.1860


Example 12



15 Step 1: To the solution of the product of Example 11, step 4 (1.4 g, 4.2 mmol) and 1-*tert*-butoxycarbonyl-4-piperidone (0.93 g, 4.67 mmol) in CH_2Cl_2 was added $\text{Ti}(\text{O}i\text{Pr})_4$ (1.19 g, 4.2 mmol) and the mixture was stirred at RT overnight. 1M Et_2AlCN (5.04 ml, 5.04 mmol) was added, the mixture was stirred overnight at RT and the solvent was evaporated. Saturated NaHCO_3 was added to the residue 20 and extractive work up with EtOAc gave the Strecker amine as a yellow syrup. The syrup was dissolved in THF (40 ml) and 3M CH_3MgBr (7 ml, 21 mmol) was added to the solution. The mixture was stirred at RT overnight, then cooled to 0° C and saturated NH_4Cl and water was added. Extractive work up with EtOAc followed by silica gel chromatography gave the piperazino-piperidine product 25 (1.78 g, 81% yield, $R_f = 0.52$, hexanes/EtOAc, 2:1).

Step 2: Treat the product of step 1 in the manner described in Example 11, Step 6, to obtain the title compound. Mp. 190° C (dec.); HRMS (as the HCl salt): found 560.2145.


Using a similar procedure, compounds of the formula



were prepared, wherein R² is as defined in the table:

Ex	R ²	mp (°C)	HRMS
12A		145 (dec.)	581.1537
12B		150 (dec.)	561.2083
12C		208 (dec.)	561.2096
12D		206 (dec.)	562.1944
12E		190 (dec.)	577.2029
12F		245 (dec.)	601.1006
12G		218 (dec.)	577.2029
12H		195 (dec.)	617.0945
12I		116 (dec.)	562.2048

Example 13



Step 1: To a solution of the N-BOC protected product of Example 11, step 4


5 (250 mg, 0.581 mmol) in DMF (2.5 ml), CuCl (1 g, 10.1 mmol) was added. The suspension was stirred under N₂ at 110°C for 24 h. After the mixture was cooled to RT, NH₄OH was added and the solution gradually turned bright blue.

Extractive work up with EtOAc gave a mixture of the chloro-substituted piperazine and its BOC derivative. After treating the mixture with TFA (5 ml) in CH₂Cl₂ (2 ml)

10 for 2 h, the solvent was evaporated and NaOH (3N) was added. Extractive work up with EtOAc afforded the pure piperazine (110 mg, 79%) as a yellow syrup.

Step 2: The product of step 1 was treated in a manner similar to Example 11, steps 5 and 6, to obtain the title compound. Mp. 180°C (dec.); HRMS (as the HCl salt): found 454.2617.


15 Using a similar procedure, compounds of the formula



were prepared, wherein R⁹ and R¹⁰ are as defined in the table:

Ex	R ⁹	R ¹⁰	Mp (°C)	HRMS
13A	-CH ₃	-NH ₂	200 (dec.)	455.2577
13B	-Cl	-NH ₂	200 (dec.)	475.2023
13C	-Cl	-Cl	187 (dec.)	494.1536




Using the product of step 1 in the procedure of Example 12, compounds of the formula




20

were prepared, wherein R² is as defined in the table:

Ex	R ²	Mp (°C)	HRMS
13D		197 (dec.)	468.2779
13E		205 (dec.)	489.2184

13F		210 (dec.)	469.2734
13G		195 (dec.)	470.2689
13H		260 (dec.)	509.1634
13I		200 (dec.)	485.2688

Example 14




Step 1: To a solution of the N-BOC protected product of Example 11, step 4 (5 g, 0.012 mol) in DMF (20 ml), CuCN (20.8 g, 0.23 mol) was added. The suspension was stirred under N₂ at 110° C for 22 h. After the mixture was cooled to RT, NH₄OH was added and the solution gradually turned bright blue. Extractive work up with EtOAc followed by silica gel column chromatography gave the cyano derivative (2.29 g, 60% yield, R_f = 0.5, hexanes/EtOAc, 4:1), the carboxamide derivative (0.95 g, 23.6% yield, R_f = 0.2, CH₂Cl₂/CH₃OH, 10:1) and the unsubstituted derivative (85 mg, 2.4% yield, R_f = 0.75, hexanes/EtOAc, 2:1).

Step 2: The BOC group on the cyano compound of step 1 was first removed

Step 2: The BOC group on the cyano compound of step 1 was first removed under acidic conditions and the resultant amine was converted to the title compound following the procedure of Example 11, steps 5 and 6. HRMS (as the HCl salt): found 445.4970.

Example 15




Step 1: To a solution of the N-BOC protected product of Example 11, step 4 (1.4 g, 3.26 mmol) and CuCl (1.61 g, 16.3 mmol) in CH₃OH at 0° C was added NaBH₄ (3.69 g, 97.6 mmol) slowly. A black precipitate was formed. The mixture was warmed to RT and stirred overnight. The precipitate was removed by celite filtration and CH₃OH was removed under vacuum. Extractive work up with EtOAc afforded the desired compound (1g, 100% yield, R_f = 0.55, hexanes/EtOAc, 5:1) as a syrup.


Step 2: The BOC group on the product of step 1 was removed under acidic conditions and the resultant amine was converted to the title compound following the procedure of Example 11, steps 5 and 6.

Mp. 195° C; HRMS (as the HCl salt): found 420.3016.

5 Using a similar procedure, the following compound is prepared:



HRMS (as the HCl salt): found 441.2426




Example 16

10 Step 1: To a solution of the N-BOC protected product of Example 11, step 4 (2.5 g, 5.8 mmol) in benzene were added phenyl boric acid (1.68 g, 13.8 mmol), 2M Na₂CO₃ (14 ml) and tetrakis(tri-phenyl phosphine) palladium (0.67 g, 0.58 mmol). The mixture was stirred under reflux overnight. Extractive work up with EtOAc followed by silica gel column chromatography gave the phenyl derivative (1.37g, 15 62% yield, R_f = 0.5, hexane/EtOAc, 5:1) as a syrup.

Step 2: The BOC group on the product of step 1 was removed under acidic conditions and the resultant amine was converted to the title compound following the procedure of Example 11, steps 5 and 6.

Mp. 190° C; HRMS (as the HCl salt): found 496.3319.


20 Using a similar procedure, compounds of the formula



were prepared, wherein R² is as defined in the table:

Sch	Ex	R ²	Mp (° C)	HRMS
223254	16A		190 (dec.)	517.2754
223255	16B		65-70*	497.3287
2?5666	16C		190 (dec.)	498.3225

* free base

Example 17


Step 1: The N-BOC protected product of Example 11, step 4 (800 mg, 1.88 mmol) was dissolved in dry THF and the temperature was brought to -78° C under N₂.

5 Butyl lithium (2.5 M solution, 0.832 ml, 2 mmol) was added and the mixture was stirred at -78° C for 10 min. The solution then was dropped into p-chlorobenzyl aldehyde (234 mg, 2.07 mmol) in THF at -78° C. The mixture was stirred for 30 min. at -78° C, then gradually warmed up to RT. Saturated NH₄Cl was added to the mixture and extractive work up with EtOAc followed by silica gel 10 column chromatography gave the desired alcohol (30 mg, 3.6% yield, R_f = 0.5, hexanes/EtOAc, 2:1) as a yellow syrup.

Step 2: A solution of alcohol of step 1 (40 mg, 0.090 mmol), triethylsilane (52 mg, 0.45 mmol) and TFA (5 ml) in CH₂Cl₂ (5 ml) was stirred under reflux conditions for 2 h. After CH₂Cl₂, triethylsilane and TFA were removed under reduced

15 pressure, NaOH solution (3N) was added to the remaining syrup. Extractive work up with EtOAc afforded the chlorobenzyl derivative (20 mg, 68% yield) as a yellow syrup..


Step 3: The product of step 2 was converted to the title compound following the procedure of Example 11, steps 5 and 6. Mp. 170° C (dec.); HRMS (as the HCl 20 salt): found 544.3101.

Example 18

25 Step 1: To a solution of the N-BOC protected 4-piperidinyl derivative of the cyano compound of Example 14, step 1 (510 mg, 1.24 mmol) in Et₂O (4 ml) was added 3M CH₃MgBr (4 ml) in a dropwise manner. The mixture was stirred under reflux overnight. After the solution was cooled on ice-bath, 12N HCl (4 ml) was added and the mixture was stirred on a steam bath for 2 h. The solution was cooled to 30 RT and solid NaOH pellets were added until the pH was more than 10. Extractive work up with EtOAc/CH₃OH (3:1) afforded the desired methyl ketone (249 mg, 61% yield) as a syrup.

Step 2: The product of step 1 was treated according to the standard DEC peptide coupling procedures of Example 11, step 6, to obtain the title compound. Mp. 210° C; HRMS (as the HCl salt): found 483.2522.

Using a similar procedure, the following compound is prepared:




18A

5

Mp. 210° C (dec.); HRMS (as the HCl salt): found 463.3088


Example 19



10

Step 1: To a solution of the product of Example 22 (140 mg, 0.29 mmol) in CH₃OH (10 ml) and EtOH (1 ml) were added NH₂OCH₃·HCl (738 mg, 8.84 mmol) and NaOAc (725 mg, 8.84 mmol). The suspension was stirred at 40 °C overnight, the solvents were evaporated and water was added to the residue. Extractive 15 work up with EtOAc followed by silica gel chromatography generated the title compound (99 mg, 68% yield, R_f = 0.38, CH₂Cl₂/CH₃OH, 20:1). HRMS (as the tartrate) calc'd. for C₃₁H₄₅N₄O₂ (M+H⁺) 505.3543; found 505.3542.

Using a similar procedure, compounds of the formula




20

were prepared, wherein R⁸, R⁶ and R² are as defined in the table:

Ex	R ⁸	R ⁶	R ²	mp (°C)	HRMS
19A		H		194 (dec.)	512.2785
19B		H		150 (dec.)	492.3344
19C		H		--	506.3494
19D		-CH ₃		180 (dec.)	508.3296

19E		-CH ₃		195 (dec.)	493.3291
-----	--	------------------	--	------------	----------


Example 20

Dissolve the free piperazino-piperidine of Example 11, step 6 (1.7 g, 3.3

5 mmol) in CHCl₃ (30ml; = Stock solution A). Add 250 ul of stock solution A (0.027 mmol) to a slurry of 0.15 g (~ 0.14 mmol) of resin bound cardodiimide (prepared by reacting Argopore-Cl resin with 1-(3-dimethyl-aminopropyl)3-ethyl carbodiimide in DMF at 100° C in DMF (1.5ml) in a polyethylene SPE cartridge. To this mixture add 75ul of a 1 M solution of 5-methyl-3-phenylisoxazole-4-carboxylic acid in DMF (0.075 mmol), and HOBT (24 ul of a 1M solution in DMF). Shake this mixture for 14 h, filter and add 0.1 g of Amberlyst-15 resin (0.47 mmol) to the filtrate. Shake for 1 to 2 h, filter and wash the resin twice with each of the following solvents THF, CH₂Cl₂ and CH₃OH, then wash with THF and CH₂Cl₂. Treat the resin with 2M NH₃ in CH₃OH (1 time for 30 min, and 1 time for 5 min). Combine and 10 concentrate the filtrates under reduced pressure to afford the title compound. LCMS found MH⁺ = 599.1 (calculated MW 598); TLC R_f = 0.74 (CH₂Cl₂/CH₃OH/NH₄OH (95/5/0.5)).

15










Using the procedure above with the appropriate carboxylic acids gave the following compounds




20

wherein R² is as defined in the table:

Ex.	R ²	LCMS results	TLC R _f values
20A		MH ⁺ = 600.1 R _t = 6.56 min.	0.92
20B		MH ⁺ = 601.1 R _t = 5.69 min.	0.63

20C		$MH^+ = 560.1$ $R_t = 5.77$ min.	0.60
20D		$MH^+ = 588.1$ $R_t = 6.61$ min.	0.66
20E		$MH^+ = 604.1$ $R_t = 5.60$ min.	0.87
20F		$MH^+ = 658.2$ $R_t = 5.69$ min.	0.86
20G		$MH^+ = 606.1$ $R_t = 6.17$ min.	0.43
20H		$MH^+ = 568.1$ $R_t = 5.67$ min.	0.57
20I		$MH^+ = 586.1$ $R_t = 6.02$ min.	0.63
20J		$MH^+ = 558.1$ $R_t = 5.35$ min.	0.33
20K		$MH^+ = 546.1$ $R_t = 5.37$ min.	0.52

Example 21



5 Step 1: The BOC group on the cyano compound of Example 14, step 1, was first removed under acidic conditions and the resulting amine (1.59 g, 6.96 mmol), 1-*tert*-butoxycarbonyl-4-piperidone (1.66 g, 8.35 mmol) and Ti(O*i*Pr)₄ (2.18 g, 7.66 mmol) in CH₂Cl₂ were stirred at RT overnight. 1M Et₂AlCN (8.35 ml, 8.35 mmol) was added, the mixture was stirred overnight at RT and the solvent was


10 evaporated. Saturated NaHCO₃ was added to the residue and extractive work up with EtOAc followed by column chromatography gave the Strecker amine as a yellow syrup (1.76 g, 58% yield, R_f = 0.70, Hexanes/EtOAc, 2:1).

Step 2: The amine of Step 1 (200 mg, 0.46 mmol) was dissolved in anhydrous THF (2 ml) and 3M CH₃MgBr (0.76 ml, 2.29 mmol) was added dropwise. The mixture was stirred at RT overnight and then cooled to 0°C. Saturated NH₄Cl (10 ml) was added and a precipitate appeared. Water (40 ml) was added and the precipitate disappeared. Extractive work up with EtOAc followed by column chromatography gave the desired ipso-methyl derivative (169 mg, 86% yield, R_f = 0.53, Hexanes/EtOAc, 2:1).

Step 3: The product of step 2 was treated in the manner described in Example 11, Step 6, to obtain the title compound. Dec. 198°C; HRMS (as the HCl salt):

10 found 460.3079.

Using a similar procedure, compounds of the formula




were prepared, wherein R² is as defined in the table:

Ex	R ²	Mp (°C)	HRMS
21A		205 (dec.)	480.2532
21B		65-75*	476.3033
21C		250 (dec.)	500.1992
21D		195 (dec.)	461.3019

15

Example 22



Step 1: The Strecker amine from Example 21, step 1 (380 mg, 0.87 mmol) was treated with CH₃MgBr (2.9 ml, 8.7 mmol) in Et₂O (5 ml) under reflux conditions


20 overnight. The mixture was cooled on ice and water (5 ml) was added dropwise. 12N HCl (6 ml) was added and the mixture was stirred on a steam bath for 2 h. After the mixture was cooled on ice, NaOH was added until the pH of the solution

was above 10. Extractive work up with EtOAc afforded a free amine as a syrup (307 mg, 100% yield).

Step 2: The product of step 1 was converted to the title compound following the peptide coupling procedure described in Example 11, step 6. Mp. 80-85° C;

5 HRMS found 476.3271.

Using a similar procedure, compounds of the formula




were prepared, wherein R² is as defined in the table:


Ex.	R ²	Mp (°C)	HRMS
22A		195 (dec.)	493.3172
22B		200 (dec.)	478.3178

10

Example 23



Steps 1-3:



15 Step 1: Ethyl diacetoacetate (93.4 g), Cs₂CO₃ (185 g) and CH₃CN (550 ml) were mixed together, using an overhead mechanical stirrer. CH₃CN (50 ml) was added and the resulting mixture was cooled to 0°C. Methyl trifluoromethane sulfonate (88.6 g) was added dropwise and after addition, the cooling bath was removed. The mixture was stirred for 1 h at RT, filtered, and the salts were washed with Et₂O (2 X 50 ml). The organic extracts were combined and Et₂O (300 ml) was added. The resulting mixture was filtered, the filter cake was washed with Et₂O (2 X 100 ml), the Et₂O extracts were combined and evaporated to half volume. The solution was cooled in an ice bath and washed once with cooled (0°C) 2 N NaOH (pH = 11). The Et₂O layer was dried over MgSO₄, filtered and evaporated to give

20

the desired product as a yellow liquid (64.7 g) in 65% yield, which was used directly in the next step.

Step 2: The product of step 1 (64.2 g), sodium ethoxide in ethanol (commercial solution; 21 wt%; 113 g) ethanol (587 ml) and formamidine acetate (36.2 g) were 5 mixed together at RT. After refluxing for 4 h, the mixture was cooled to RT, the resulting precipitate was filtered off and the ethanol was removed under vacuum. The resulting liquid was partitioned between water and CH_2Cl_2 and the aqueous layer was extracted with CH_2Cl_2 (3 x 150 ml). The CH_2Cl_2 extracts were dried over MgSO_4 , filtered and evaporated to give a dark crude liquid (50.7 g) which 10 was purified by silica gel chromatography (980 g; 4:1 hexanes:EtOAc as eluant). After evaporation of the appropriate fractions, the desired product (28.5 g) was isolated in 46% yield and used directly in the next step.

Step 3: The product of step 2 (28.1 g), NaOH (6.72 g), water (65 ml) and EtOH (130 ml) were mixed together at RT and heated at reflux for 1h. The resulting 15 solution was cooled to RT and the volatile materials were removed in vacuo until a thick paste resulted. Water (20 ml) was added, the mixture was cooled to 0°C and conc. HCl (14.3 ml) was added dropwise with stirring. The resulting white precipitate was collected by filtration, washed with ice water (2 X 10 ml) and air dried with suction for 30 min. The resulting white solid was treated with toluene (2 20 x 20 ml), the solvent was removed in vacuo at 50°C and then dried under vacuum (1 mm Hg) for 18 h. The desired product (14.9 g) was isolated as a white solid in 63% yield, mp: 176-178°C. Elemental analysis of $\text{C}_7\text{H}_8\text{N}_2\text{O}_2$: calc'd C 55.26%, H 5.30%, N 18.41%; found: C 55.13%, H 5.44%, N 18.18%.

A second crop of product was isolated by evaporation of the aqueous 25 filtrate (from above) to dryness and addition of water (20 ml). The resulting mixture was stirred at RT for 5 min, cooled in an ice bath and the precipitate formed was collected by filtration. The resulting solid was washed with ice water (2 X 5 ml) and dried as described above to give the product (4.68 g) as a cream colored solid to give a combined yield of 83%.


30 Step 4: The product of Example 4, step 6 (trihydrochloride form; 5.4 g), DMF (11.3 ml), HOBt (3.07 g), diisopropyl ethyl amine (12.3 ml) and the product of step 3 (3.45 g) were mixed together and DEC (4.35 g) was added in portions over 15 min. The resulting mixture was heated at 45°C for 18 h, cooled to RT, diluted with EtOAc (80 ml) and washed with 2 N NaOH (25 ml). The aqueous layer was 35 extracted with EtOAc (3 x 25 ml), the organic extracts were combined, washed with brine, dried over Na_2SO_4 , filtered and evaporated. The resulting crude oil was purified by silica gel chromatography (170 g; 76:19:5 hexanes:EtOAc:Et₃N as

eluant). After evaporation of the appropriate fractions, the free base form of the title compound (5.21 g) was isolated as a light colored foam in 91% yield.


Step 5: To a cooled (0°C) solution of the free base of step 4 (2.00 g) and EtOAc (20 ml) was added HCl (3.0 ml of a 4.0 M solution in 1,4-dioxane). The resulting mixture was warmed to RT, diluted with Et₂O (20 ml), filtered, washed with Et₂O (2 X 20 ml), air dried with suction for 10 min and then under vacuum (1 mm Hg) at 90°C for 5 h to give the title compound (2.30 g) as a white solid in 97% yield. mp: 159-162°C.

Elemental analysis of C₂₇H₃₆N₅OF₃•2HCl•0.5H₂O: calc'd: C 55.38%, H 6.71%, N 11.96%, Cl 12.11%; found: C 55.19%, H 6.69%, N 11.75%, Cl 11.45%.

Additional pyrimidine derivative-compounds were made using similar procedures:



Steps 1-2:




15

Step 1: The product of Example 23, step 1 was treated in the same manner as in Example 23, step 2, substituting acetamidine hydrochloride (2.03 g) for formamidine acetate. The amounts of the reagents were: product of Example 23, step 1 (4.0 g), ethanol (20 ml) and sodium ethoxide in ethanol (commercial solution; 21 wt%; 8.03 g). After extraction and purification as described above, the product was isolated (1.7 g) as a colorless liquid in 41% yield, which was used directly in the next step.


Step 2: The product of step 1 (1.7 g) was treated in the same manner as Example 23, step 3, using ethanol (5 ml), water (5 ml) and NaOH (1.0 g). After extraction and purification as described above, the product was isolated (0.12 g) as a white solid in 8% yield, which was used directly in the next step.

Step 3: The product of Example 4, step 6 (0.05 g), and the product of step 2 (immediately above) (0.028 g) were subjected to the same reaction conditions as in Example 23, step 4, using HOEt (20 mg), DEC (45 mg), diisopropyl ethylamine (40 mg) and DMF (1.5 ml). After extraction and purification as described above, the product was converted to its HCl salt using the procedure outlined for

Example 23, step 5 to give the title compound (77 mg) as a white solid in 97% yield over the two steps. mp: 185-190°C.



Steps 1-2:




5


Step 1: The product of Example 23, step 1 was treated in the same as in Example 23, step 2, substituting benzamidine hydrochloride (3.35 g) for formamidine acetate. The amounts of the reagents were: product of Example 23, step 1 (4.0 g), ethanol (20 ml) and sodium ethoxide in ethanol (commercial 10 solution; 21 wt%; 8.03 g). After extraction and purification as described above, the product was isolated (4.5 g) as a liquid in 82% yield which was used directly in the next step.

10 Step 2: The product of step 1 (4.5 g) was treated in the same manner as Example 23, step 3, using ethanol (10 ml), water (10 ml) and NaOH (2.0 g). After 15 extraction and purification as described above, the product was isolated (3.0 g) as a white solid in 77% yield which was used directly in the next step.

15 Step 3: The product of Example 4, step 6 (75 mg), and the product of step 2 (immediately above) (39 mg) were subjected to the same reaction conditions as in Example 23, step 4, using HOEt (35 mg), DEC (53 mg), diisopropyl ethylamine 20 (100 mg) and DMF (2 ml). After extraction and purification as described above, the product was converted to its HCl salt using the procedure outlined for Example 23, step 5 to give the title compound (98 mg) as a white solid in 96% yield over the two steps. mp: 250-253°C.



25 Steps 1-2:



Step 1: The product of Example 23, step 2 (528 mg) was dissolved in CH₂Cl₂ (5.0 ml) and meta-chloroperbenzoic acid (mCPBA) (600 mg) was added in three portions at RT. The resulting mixture was stirred at RT for 24 h and CH₂Cl₂ (2 ml) and mCPBA (200 mg) were added. After 3 h, the mixture was poured onto a 5 silica gel column (40 g) and eluted with 1:1 hexanes:EtOAc and then 10:1 CH₂Cl₂:CH₃OH. After evaporation of the appropriate fractions, the product was isolated (512 mg) as a waxy white solid in 89% yield, which was used directly in the next step.


Step 2: The product of step 1 was dissolved in CH₃OH (1.8 ml) and a solution of 10 1.0 M Na₂CO₃ (1.5 ml) was added. After stirring at RT for 36 h, the resulting mixture was evaporated to dryness, toluene (2 ml) was added and the mixture was evaporated to dryness. The resulting crude solid (153 mg) was used directly in the next step without purification.

Step 3: The product of Example 4, step 6 (94 mg), and the product of step 2 15 (immediately above) (76 mg) were subjected to the same reaction conditions as in Example 23, step 4, using HOEt (92 mg), DEC (130 mg), diisopropyl ethylamine (0.14 ml) and DMF (0.25 ml). After extraction and purification by preparative thin layer chromatography (1000 μ M silica plate; 95:5 EtOAc:Et₃N eluant), the free base form of the title compound was isolated (52 mg) as a foam in 40% yield.

20 HRMS: calc'd: M·H⁺: C₂₇H₃₇N₅O₂F₃: 520.2899; measured: 520.2908.

Step 4: The product of step 3 (52 mg) was subjected to the reaction conditions in Example 23, step 5, using EtOAc (1.0 ml) and HCl (4.0 M solution in 1,4-dioxane; 75 μ l) to give, after work up, the title compound (44.5 mg) as a white solid in 76% yield. mp: decomposition above 161°C.

25 Using similar procedures, the compounds of the formula




were also prepared, wherein R^{8a} and R¹¹ are as defined in the table:

Ex.	R ^{8a}	R ¹¹	m.p. (°C)
23D	-CF ₃	-OH	175-185
23E	-CF ₃	-OCH ₃	169-173
23F	-CF ₃	-NH ₂	200-210
23G	-CF ₃	-NHCONHEt	184-190
23H	-CF ₃	-CF ₃	83-86

23I	-CF ₃		154-159
23J	-CF ₃	-SCH ₃	>176 (dec)
23K	-OCF ₃	-CH ₃	205-210
23L	-OCF ₃	Ph	239-242
23M	-OCF ₃	-OCH ₃	200-210
23N	-OCF ₃	-OH	185-191

Example 24
Arylcyclopropylamides

Method A:



5

Step 1: To the stannane (0.39 g, 0.95 mmol) in DMF (10 ml) was added the 2-chloro-4-fluoriodobenzene (0.73 g, 2.86 mmol), CuI (0.19 g, 1.05 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.11 g, 0.095 mmol). The reaction was stirred at RT under N₂ for 21 h. The reaction mixture was added to Et₂O and the heterogeneous solution filtered through a bed of celite, washing with EtOAc. The filtrate was washed with water and brine and dried (MgSO₄). Filtration and evaporation of the solvent in vacuo afforded a residue that was preadsorbed on silica gel. Purification by silica gel chromatography (4% EtOAc/hexane) yielded the arylacrylate (0.19 g, 78%), which was used directly in the next step.


10 Step 2: To trimethylsulfoxonium iodide (0.18 g, 0.81 mmol) in DMSO (1.6 ml) was added potassium *tert*-butoxide (0.09 g, 0.81 mmol). The reaction mixture was stirred at RT for 1 h, at which time the arylacrylate (0.19 g, 0.74 mmol) in DMSO (1.6 ml) was added. The reaction mixture was stirred at RT for 5 h and water was added. The mixture was extracted with EtOAc. The combined organic layers were washed with water and brine and dried (MgSO₄). Filtration and evaporation of the solvent in vacuo afforded the arylcyclopropyl ester that was used directly by taking up into CH₂Cl₂ (3 ml) and adding TFA (0.5 ml). The reaction mixture was stirred at RT for 15 h and then concentrated in vacuo to afford the arylcyclopropylcarboxylic acid (0.14 g, 91%-2 steps). Without further purification,

15

20

the carboxylic acid was coupled to the product of example 8, step 3, using the procedure of Example 8, step 4 to obtain **24A** as the HCl salt. HRMS (M+H): found 566.2561.


Method B:




















5

To the 2-fluorophenylacetonitrile (0.80 g, 5.92 mmol), benzyltriethylammonium chloride (0.03 g, 0.12 mmol), and 1-bromo-2-chloroethane (1.70 g, 11.9 mmol) was added 50% aqueous NaOH (3.5 ml). The reaction was stirred at 45 °C for 21 h and ethylene glycol was added (3 ml). The reaction was then warmed to 100 °C and stirred for 7 h. Upon cooling to RT, the reaction was diluted with water and washed with EtOAc. The aqueous layer was acidified to pH 2-3 with aqueous 6N HCl. The acidified solution was extracted with Et₂O. The combined Et₂O extracts were washed with water and brine and dried (MgSO₄). Filtration and evaporation of the solvent in vacuo afforded a pale yellow solid (1.06 g, 99%). The arylcyclopropyl acid was coupled to the product of example 8, step 3, using the procedure of Example 8, step 4 to obtain **24B** as the HCl salt. HRMS (M+H): found 532.2949.



Using similar procedures, the compounds of the formula



20 were prepared, wherein  is as defined in the table:


Ex.		HRMS (M+H)	m.p. (°C)
24C		--	240-245
24D		--	>225
24E		--	172-176
24F		--	225-230
24G		--	>225
24H		544.3151	--
24I		592.2150	--
24J		532.2956	--
24K		539.3003	--
24L		558.2949	--
24M		572.3107	--
24N		582.2910	--
24O		582.2910	--
24P		520.2609	--
24Q		515.2991	

Example 25

5 Step 1:

Cyclopropyl carboxaldehyde (3.4 ml), S-methyl N-BOC piperazine (8.28 g), CH₂Cl₂ (82 ml) and Ti(OiPr)₄ (15.80 ml) were mixed together and stirred at RT for 23 h, then the resulting solution was cooled to 0 °C and Et₂AlCN (1.0 M in


10 toluene; 62.1 ml) was added. The solution was stirred for 5 h at RT. A mixture of KF (20 g) and Celite (10 g) was added, followed by cautious addition of EtOAc (120 ml) and water (120 ml). The resulting slurry was stirred for 15 min, filtered, washed with EtOAc (3 X 35 ml) and the EtOAc layer was removed, washed with brine, dried over Na₂SO₄, filtered and evaporated to give the desired intermediate 15 (12.0 g) which was used directly in the next step.

Step 2:

To a 0 °C solution of 4-iodobenzotrifluoride (40 g) and THF (52 ml) was added isopropyl magnesium chloride (2.0 M in Et₂O; 74 ml). The resulting 20 solution was stirred at RT for 1 h and then added to a 0 °C solution of the product of step 1 (10.0 g) and THF (26 ml) over 10 min. The reaction solution was warmed to RT, stirred overnight and EtOAc (50 ml) was added. After stirring for 10 min, 2 N NaOH (50 ml) was added and the resulting mixture was stirred for 30 min, filtered and the salts were washed with EtOAc (3 X 20 ml). The combined 25 EtOAc extracts were washed with brine, dried over Na₂SO₄, filtered and evaporated to give the crude product (28 g) as a gold oil which was chromatographed on silica gel (1 kg), eluting with hexanes:EtOAc (8:1). Two diastereomeric products were collected as a single fraction (15.9 g) and further purified by column chromatography as described above to give intermediate A 30 (R_f=0.47 in 4:1 hexanes:EtOAc; 5.34 g), which was contaminated with an


unidentified impurity. (The second diastereomer B ($R_f=0.29$ in 4:1 hexanes:EtOAc) was also collected.)

Step 3:



5 To a solution of A from Step 2 (3.96 g) and CH_2Cl_2 (120 ml) was added DOWEX 50X2-100 ion exchange resin (15 g) and the resulting mixture was shaken for 2.5 h at RT. The resin was filtered off and washed with CH_2Cl_2 (2 X 40 ml). The resin was treated with 7 N NH_3 in CH_3OH (30 ml), the resin was filtered off and this procedure was repeated two times. The CH_3OH extracts were 10 combined and evaporated. The resulting oil was treated with toluene: CH_2Cl_2 (1:1; 15 ml) and evaporated to give the piperazine intermediate (0.80 g) as a clear oil. HRMS: calc'd: M^+H^+ : $\text{C}_{16}\text{H}_{21}\text{N}_2\text{F}_3$:299.1735; measured:299.1748.

Step 4:




15 The product of Step 3 (0.57 g) was treated in the same fashion as Example 8, Step 1, using N-BOC 4-piperidone (0.42 g), CH_2Cl_2 (3.84 ml), $\text{Ti}(\text{O}i\text{Pr})_4$ (3.39 ml), Et_2AlCN (2.88 ml) and CH_3MgBr (3.0 M in Et_2O ; 3.2 ml) to give the desired product (0.78 g) as a clear oil in 82 % yield.

Step 5: The product of Step 4 (0.12 g) was treated with $\text{AcOH}:\text{CH}_2\text{Cl}_2$ (3:1, v:v; 1.4 ml) followed by $\text{BF}_3\text{Et}_2\text{O}$ (0.14 ml). After stirring for 1 h, the resulting solution was diluted with CH_2Cl_2 (10 ml), cooled to 0°C and the pH was adjusted to 10 with solid NaOH . Water (2 ml) was added and the CH_2Cl_2 layer was removed. After further extraction (2 X 10 ml) with CH_2Cl_2 , the organic layer was washed with water, brine, dried over Na_2SO_4 , filtered and evaporated to give the free piperidine (80 mg) in 81 % yield.

Step 6: The product of Step 5 (57 mg) was treated in the same fashion as in Example 8, Step 4, using DMF (0.30 ml), HOBt (41 mg), DEC (57 mg), diisopropyl ethyl amine (0.08 ml) and 4,6-dimethyl 5-pyrimidine carboxylic acid (43 mg); the reaction was stirred at 45°C for 5 h. Purification of the crude oil was carried out 30 by preparative plate chromatography (silica adsorbent; 2000 μM ; 76:19:5 EtOAc:hexanes:Et₃N as eluant) to give, after elution of the desired band (1:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$) and concentration of solvent, the title compound (70 mg) as a


clear oil in 93% yield. The HCl salt was prepared as described for Example 8, Step 4 (78 mg) in 100% yield. mp:147-149°C.

Using a similar procedure, the following compound was prepared:




5 m.p. >188 (dec).

Example 26




Step 1:



10 The desired compound was prepared in a manner similar to Example 25, Step 1, using p-trifluoromethyl benzaldehyde (20 g) instead of cyclopropyl carboxaldehyde, to give, after work up, a mixture of diastereomers (22.7 g) in 59% yield.


15 Step 2:



To a -70°C solution of the product of step 1 (1.9 g) and THF (15 ml) was added NaHMDS (1.0 M in THF; 7.5 ml) followed by benzyl bromide (2 ml). The cooling bath was removed and the resulting solution was stirred for 45 min.

20 Concentrated NH₄OH (10 ml) was added and the reaction was stirred for 30 min. The resulting mixture was partitioned between water and CH₂Cl₂, the CH₂Cl₂ extracts were removed and evaporated and the crude oil was purified by column chromatography (silica gel; 2:1 hexanes:CH₂Cl₂; 10:1 to 7:1 hexanes:EtOAc as eluant) to give, after evaporation of the appropriate fractions, a mixture of 25 intermediates (1.92 g) as a yellow foam.

Step 3:



The mixture of Step 2 (1.91 g), CH₃CN (35 ml), sodium triacetoxy borohydride (4.0 g) and magnesium bromide etherate (2.25 g) were mixed and stirred at RT for 70 h. Water (25 ml) was added and then, gradually, a solution of

5 Na₂CO₃ (10 g) in water (50 ml). After extraction with EtOAc (2 X 50 ml), drying and evaporation of the organic layer, the resulting oil was purified by preparative plate chromatography (5 X 2000 mM silica plates; 6:1 hexanes:EtOAc as eluant). The less polar band was removed, treated with 1:1 methanol:CH₂Cl₂, filtered and evaporated to give intermediate A (0.84 g) as a white foam. HRMS: calc'd: M·H⁺:

10 C₂₅H₂₉O₂N₂F₃:449.2407; measured:4492416.


Step 4: The product of Step 3 (0.81 g) was treated in the same fashion as in Example 8, Step 3, using TFA (5 ml) and CH₂Cl₂ (10 ml), to give, after work up, the free piperazine (0.60 g) as a clear gum. HRMS: calc'd: M·H⁺: C₂₀H₂₃N₂F₃: 349.1892; measured:349.1894.

15 Step 5: The product of Step 4 (0.39 g) was treated in the same fashion as in Example 8, Step 1, using N-BOC 4-piperidone (0.25 g), CH₂Cl₂ (8 ml), Ti(O*i*Pr)₄ (0.40 mg), Et₂AlCN (2 ml) and CH₃MgBr (3.0 M in Et₂O; 1.5 ml) to give the desired BOC-protected piperidinyl intermediate (0.44 g) as a clear oil in 72 % yield. HRMS: calc'd: M·H⁺: C₃₁H₄₂O₂N₃F₃:546.3307; measured:546.3315.

20 Step 6: The product of step 5 (0.43 g) was treated in the same fashion as in Example 8, Step 3, using TFA (3 ml), CH₂Cl₂ (2 ml) and water (0.2 ml) to give, after work up, the free piperidinyl intermediate (0.37 g) as a clear oil.

25 Step 7: The product of step 6 (50 mg) was treated in the same fashion as in Example 8, Step 4, using CH₂Cl₂ (3 ml), HOEt (28 mg), DEC (40 mg), diisopropyl ethyl amine (42 mg) and 4,6-dimethyl 5-pyrimidine carboxylic acid (24 mg); the reaction was stirred at RT for 2 days. Using the procedure described in Example 8, Step 4, the HCl salt of the title compound was prepared (59 mg) in 91% yield (from the product of Step 5). M.p:187-196 °C. HRMS: calc'd: M·H⁺: C₃₃H₄₀ON₅F₃:580.3263; measured:580.3263.

30 Using a similar procedure, compounds of the formula




were prepared, wherein R^{8a}, R³ and R² are as defined in the table:


Ex.	R ^{8a}	R ³	R ²	Mp (°C)
26B	-CF ₃			86-92
26C	-CF ₃			83-90
26D	-CF ₃			195-205
26E	-CF ₃			118-125
26F	-OCF ₃			175-185
26G	-OCF ₃			180-190
26H	-OCF ₃			220-230
26I	-OCF ₃			195-210
26J	-OCF ₃			190-200
26K	-OCF ₃			180-205
26L	-OCF ₃			230-240
26M	-OCF ₃			60-65
26N	-OCF ₃			65-68
26O	-OCF ₃			60-62

26P	-CF3			256-258
26Q	-CF3			254-256 (dec)
26R	-CF3			249-250 (dec)

Example 27



5 Step 1:



4'-Trifluoromethyl)propiophenone (2.02 g, 0.01 mol) and (S)-2-methyl-CBS-oxazaborolidine (1M in THF) (2.0 ml, 0.002 mol) in THF (10 ml) was cooled in an ice-bath and borane-methyl sulfide complex (2M in THF) (3 ml, 0.006 mol) was added dropwise to the mixture. The mixture was stirred for 30 min at 0° C and CH₃OH was added slowly until no bubbles appeared. The solvents were removed under reduced pressure and HCl solution (1N) was added to the mixture. EtOAc extractive work up followed by silica gel chromatography afforded the alcohol (1.47 g) in 72% yield.

15 Step 2: A solution of the product of Step 1 (4.32 g, 0.021 mol) and Et₃N (5.9 ml, 0.042 mol) in CH₂Cl₂ (20 ml) was cooled to 0° C in ice bath and CH₃SO₂Cl (2.13 ml, 0.028 mol) was added dropwise. The mixture was stirred at 0° C for 1 h and the ice bath was removed. Water was added to the mixture and CH₂Cl₂ extractive work up afforded the mesylate (5.99 g) in quantitative yield.

20 Step 3: The product of Step 2 (5.93 g, 0.021 mol) and 1-*tert*-butoxy-carbonyl-3S -
methyl piperazine (4.2 g, 0.021 mol) were dissolved in anhydrous CH₃CN (20 ml)
and oven-dry K₂CO₃ (4.35 g, 0.032 mol) was added to the solution. The mixture
was stirred under reflux for 2 days, then diluted with water. EtOAc extractive work
up followed by silica gel chromatography gave the desired product (3.16 g) in
25 39% yield.

Step 4: TFA (10 ml) was added to a solution of the product of Step 3 (1.15 g, 2.59 mmol) in CH_2Cl_2 (5 ml) and the mixture was stirred at RT for 2 h, then concentrated under reduced pressure. NaOH (3N) was added to the residue and extractive work up with EtOAc gave the desired amine in quantitative yield.

5 Step 5: The product of Step 4 and 1-*tert*-butoxycarbonyl-4-piperidone (0.94 g, 4.74 mmol) were treated with $Ti(OiPr)_4$, Et_2AlCN and CH_3MgBr in a manner similar to that described in Example 8, step 1, to obtain the desired product (1.09 g) in 87% yield (from the amine of Step 4).


Step 6: TFA (4 ml) was added to a solution of the product of Step 5 (0.76 mg,

10 1.57 mmol) in CH_2Cl_2 (2 ml) and the mixture was stirred at RT for 2 h before it was concentrated under reduced pressure. NaOH (3N) was added to the residue and extractive work up with EtOAc gave the desired amine in quantitative yield.





Step 7: The amine of Step 6 and 4,6-dimethylpyrimidine 5-carboxylic acid (0.36 g, 2.35 mmol), were coupled as described in Example 8, Step 4, to obtain the title

15 compound (0.58 g) in 72% yield. M.p. 160; HRMS (MH⁺) found: 518.3123.





Using a similar procedure, compounds of the formula





were prepared wherein Z, R³, R⁶ and R² are as defined in the table below:

Ex.	Z	R ³	R ⁶	R ²	Dec.(0°C)	HRMS
27A	N	Me	H		185	491.2744
27B	N	Me	H		190	506.2729
27C	N	Me	Me		190	505.2898
27D	N	Me	Me		200	520.2902

27E	CH	Et	Me		197	533.3097
27F	CH	Et	Me		215	532.3147
27G	CH	Et	Me		230	627.3145
27H	CH	Et	Me		210	602.3678
27I	CH	Et	Me		215	531.3305
27J	CH	Et	Me		215	593.3470
27K	CH	Et	Me		195	609.3424
27L	CH	Et	Me		170	745.2308
27M	N	n-Pr	Me		204	533.3207
27N	N	n-Pr	Me		210	617.3798


27O	N	n-Pr	Me		202	531.3304
27P	N	n-Pr	Me		165	543.3311
27Q	N	n-Pr	Me		225	584.3205
27R	N	n-Pr	Me		195	548.3217

Using similar procedures, the following compounds were also prepared:




5

Example 28



Steps 1-4:



Step 1: The cyano amine was prepared from p-trifluoromethyl benzaldehyde and 2(S)-methyl-4-(tert-butoxycarbonyl) piperazine exactly as described in Example 6, Step 1.

5 Step 2: A solution of the cyano amine 2 (2.5 g; 6.53 mmol) in 30 ml of dry THF was placed under a blanket of N₂ and cooled to -78⁰ C. This solution was treated with a solution of sodium hexa-methyl disilazide in THF (1M; 26 ml) followed after 5 min with neat allyl bromide (6 ml). Upon removal of the bath and letting the reaction mixture warm to RT (~1h), it changed from a yellow solution to dark reddish brown solution. The reaction was quenched with saturated NH₄Cl solution and the product extracted with EtOAc, washed with water, brine and dried. Concentration in vacuo afforded a brown semi solid. FSGC of this material using 25% Et₂O in hexane as eluant gave 2.5 grams (92%) of the desired product as an amber gum (TLC R_f = 0.65, 0.6 for two overlapping spots).

10 15 Step 3: A solution of the product of Step 2 (2.4g) in CH₃OH was treated with 10% Pd/C (0.2g) and placed under a balloon of H₂ gas. After stirring at RT for 4 h, the catalyst was removed via filtration through celite. Concentration of the filtrate yielded an amber gum.

The α -propyl nitrile obtained above was dissolved in CH₃CN (12 ml).

20 Magnesium bromide etherate (2.1 g; 8.14 mmol) and sodium triacetoxy borohydride (3.44 g; 16.2 mmol) were added and the reaction mixture was stirred at RT overnight. The reaction was quenched with water and rendered basic with saturated NaHCO₃. The organic products were extracted with EtOAc and processed to obtain ~ 2 g of crude material. FSGC (10-25% Et₂O in hexane) served to isolate two diastereomeric products (1.7g total; 79% for two steps): (S, S)-Diastereomer (**A**): TLC R_f = 0.6 (25% Et₂O-Hexane). 0.9 g of a colorless gum.


(R, S)-Diastereomer (**B**): TLC R_f = 0.5 (25% Et₂O-Hexane). 0.8 g of a colorless gum.

25 30 Step 4: Removal of the BOC-protecting group from the intermediate **A** was accomplished by treatment with TFA in CH₂Cl₂. The isolated free piperazine

(0.68g; 2.3 mmol), N-(tert-butoxycarbonyl)-4-piperidinone (0.45g; 2.3 mmol) and Ti(O*i*Pr)₄ (0.7 mL; 2.5 mmol) were dissolved in 10 ml of CH₂Cl₂ and stirred overnight. Et₂AlCN (1M in toluene; 2.7 ml) was introduced into the reaction mixture and the resultant solution was stirred for a day. The reaction was diluted with EtOAc and quenched with water. Celite was added to aid in the filtration of titanium and aluminum salts. The biphasic filtrate was washed with water, brine and dried. Concentration in vacuo yielded 1.1 g of a yellow gum (TLC R_f = 0.55 in 25% EtOAc-hexane).

The resultant ipso-cyano compound was dissolved in dry THF (8 ml) and treated with a solution of CH₃MgBr (3M in Et₂O; 6 ml) and stirred overnight at RT. The reaction flask was placed in a cold water bath and carefully quenched with saturated NH₄Cl solution. The organic product was extracted with EtOAc and washed with water and brine. Concentration to a crude product which was purified by rapid FSGC (10-25% EtOAc in hexane) gave the BOC-piperidinyl compound as a pale yellow gum (1.1g; 100%). TLC R_f = 0.6 in 25% EtOAc-hexane.

Step 5: The BOC-protecting group on the piperidine nitrogen in the product of Step 4 was removed by treatment with TFA in CH₂Cl₂. Basification with 1 M NaOH and processing in CH₂Cl₂ afforded the unprotected piperidine in 90% yield. This intermediate was coupled (EDCI, HOt) to aryl and heteroaryl carboxylic acids to obtain the amides exemplified in the following table:




wherein R² is as defined in the table:

Ex.	R ²	Mp (°C)	HRMS (MH ⁺)
28A		249	Calculated: 532.3263 Found: 532.3268

28B		59	Calculated: 547.3260 Found: 547.3278
28C		246	Calculated: 530.3358 Found: 530.3372
28D		239	Calculated: 542.3358 Found: 542.3361
28E		258	Calculated: 583.3260 Found: 583.3272
28F		102	Calculated: 623.3573 Found: 623.3572
28G		216	Calculated: 545.3467 Found: 545.3459
28H		217	Calculated: 546.3307 Found: 546.3309
28I		223	Calculated: 616.3838 Found: 616.3848

Using similar procedures, the following compounds were prepared:




wherein R⁸, R³ and R² are as defined in the table:

Ex.	R ⁸	R ³	R ²	Mp (° C)
28J	-CF ₃			195-220


28K	-CF ₃			105-115
28L	CH ₃ CONH-			177-180
28M	-CF ₃			224-232

Using 3-fluoro benzyl bromide or chloride in place of benzyl bromide in the procedure of Example 28, steps 1-4 (processing isomer B in step 3), then using the process of Example 1, step 5, followed by the process of Example 26, steps 6-7, the following compound was prepared (HCl salt):




5 **28N:** m.p. 185-193 °C

Example 29



10 **Steps 1-3:**



Step1: Solid m-CPBA was added to a solution of p-trifluoromethyl styrene (3g; 17.4 mmol) in 30 ml of CH₂Cl₂ and stirred at RT for 20 h. About 20 ml of a saturated solution of NaHCO₃ was added and stirred at RT for 2 h. The mixture was diluted with 20 ml of CH₂Cl₂ and the organic product extracted into the CH₂Cl₂ layer. The organic extract was processed to obtain the crude product.

FSGC gave 3g (90%) of the desired epoxide as a colorless oil. TLC R_f = 0.8 (25% EtOAc in hexane).

Step 2: Freshly prepared NaOCH₃ (0.6g; 10.6 mmol) was added to a solution of the product of Step 1 (2g; 10.6 mmol) in 20 ml of anhydrous CH₃OH. After stirring at RT for a day, CH₃OH was removed in vacuo. The residue was dissolved in CH₂Cl₂ and washed with water and brine. Concentration, followed by FSGC, furnished 1.3 g (55%) of the carbinol as a colorless oil (R_f = 0.3 50% Et₂O in hexane).

Step 3: The carbinol of Step 2 (1.3g; 5.9 mmol) was dissolved in CH₂Cl₂ and cooled in an ice bath. Sequential treatment with Et₃N (1.7 ml; 12 mmol) and CH₃SO₂Cl (0.6 ml; 7.7 mmol) and stirring for 30 min formed the mesylate. The product was extracted by standard work up (yield = 100%).


The mesylate (1.76g; 5.9 mmol) and 2(S)-methyl-4-(tert-butoxycarbonyl) piperazine (2.4 g; 12 mmol) were dissolved in 5 ml of CH₃CN and heated to reflux for 19 h. The reaction mixture was cooled to RT and directly subjected to flash chromatography on silica gel. Eluting with 25%, then 50% Et₂O in hexane served to isolate the diastereomeric products **A** and **B** (Total yield = 86%).

A: R_f = 0.5 (50% Et₂O in hexane). Light yellow gum (0.9g; 42%)

B: R_f = 0.4 (50% Et₂O in hexane). Amber gum (1.13g; 44%)

Step 4: Reductive amination of the free piperazine derived from **A** (0.9g; 2.2 mmol) with N-BOC-piperidin-4-one with the installation of the ipso-methyl group was carried out as described in Example 1, step 4. to obtain the BOC-protected piperidinyl compound (0.87g; 92%). R_f = 0.3 (50% EtOAc in hexane).

Step 5: The BOC protecting group was removed from the piperidine nitrogen via TFA, and the resultant compound was coupled with acids using the EDCI / HOBr method as described in Example 8, step 4, to obtain the compounds shown in the following table:




wherein R² is as shown in the table:

30

Ex.	R ²	Mp (°C)	HRMS (MH ⁺)
29A		163	Calculated: 534.3056 Found: 534.3050

29B		208	Calculated: 548.3100 Found: 548.3092
29C		101	Calculated: 549.3053 Found: 549.3057
29D		192	Calculated: 618.3631 Found: 618.3638


Example 29E

5 The piperidine **A** (130 mg), 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (130 mg), 1-hydroxybenzotriazole (92 mg), and diisopropylethylamine (0.3 mL) were taken up in CH_2Cl_2 and stirred at 25 °C for 19 h. The solution was diluted with CH_2Cl_2 and washed with 1 N NaOH (aq.). The aqueous layer was extracted with CH_2Cl_2 and dried over MgSO_4 . Filtration and 10 concentration gave a yellow oil. Purification via preparative thin-layer chromatography (10/1 acetone/hexanes, SiO_2) gave 95 mg (51 %) of compound 29E as a colorless oil. HRMS calcd (MH^+): 550.3005; Found: 550.3000.

A was prepared according to Steps 1-5 for Example 29 set forth above.

15 The pyrimidine acid was prepared according to the procedure outlined for Example 23C Steps 1 and 2 set forth above.


Compound 29E can also be isolated as the metabolite of compound 29A in plasma, urine, bile or fecal sample of a patient who has been administered compound 29A as set forth below in Example 29F. In addition to compound 29E, other compounds that can be isolated as metabolites in human or other animal 20 species include the following:



Example 29F – Isolation of Metabolites

5

Chemicals: ^{14}C -Vicriviroc [1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-[4-(trifluoromethyl)phenyl]ethyl]-3(S)-methyl-1-piperazinyl]-4-methylpiperidine, i.e., ^{14}C -compound 29A shown below]



10

Vicriviroc (compound 29A; * designates position of ^{14}C radiolabel)

was synthesized at Schering-Plough Research Institute (Kenilworth, NJ) and had >97% radiochemical purity. All other compounds/reference standards were obtained from the Department of Chemical Research at Schering-Plough

15

Research Institute. HPLC grade acetonitrile and methanol were from Burdick

and Jackson (Muskegon, MI). Water was purified using the Millipore Milli-Q_{plus} water purification system (Bedford, MA).

Test Species:

Species	Age	Weight or Body Mass Index (BMI)	Oral Dose
Human (M) (n=8)	18-50 yr	BMI = 19-29 kg/m ²	50 mg ¹⁴ C-compoud 29A maleate (100 µCi) in water
Monkey (M & F) (n=4) (Strain: Cynomolgus macaque)	2-5 yrs	2-5 kg	5 mg/kg (25.8 µCi/mg) ¹⁴ C-compound 29LA in water
Rat (M & F) (n=3) (Strain: Sprague Dawley)	7-10 wk	175-270 g	6 mg/kg (12.3 µCi/mg) ¹⁴ C-compound 29A in 0.4% methylcellulose

M = Male; F = Female; n = number of animals/subjects per gender

5 **Sample Collection:** Urine and feces over selected intervals and blood at selected time points were collected from healthy male volunteers, monkeys and rats through 336-hr, 432-hr and 168-hr post dose, respectively.

Radioactivity: Total radioactivity was measured using liquid scintillation

10 spectrometer (LSS).

Sample Processing for Profiling and Characterization of Metabolites:

Sample Pooling:

For each species, plasma samples were pooled across subjects/animals by time point. All the other matrices were first pooled for a desired collection interval

15 within each subject/animal and then across subjects/animals to obtain a composite sample containing >90% of the radioactivity excreted in each respective matrix.

Species	Plasma (hr)	Urine (hr)	Feces (hr)
Human	Pre-dose ^a , 4, 8 & 24	0-96	0-264
Monkey	Pre-dose, 1 & 4	0-168	0-72
Rat	Pre-dose, 2, 8, 12 & 24	0-48 (M) & 0-72 (F)	0-72

a: Pre-dose plasma was used for optimizing extraction procedure/conditions
M = Male and F = Female

Sample Processing:

Matrix	Methods
Plasma	SPE using Oasis HLB cartridges (Waters Corp., Milford, MA) or Solvent extraction with protein precipitation using acetonitrile
Urine	SPE using Oasis HLB cartridges (Waters Corp., Milford, MA) or direct Injection
Feces	Solvent extraction using methanol

5

Mobile Phase and HPLC Conditions:

HPLC column was maintained at room temperature for all LC-MS and LC-MSⁿ experiments. The mobile phase, which consisted of 95% 10-mM ammonium acetate (pH 6.0) containing 5% acetonitrile (A) and 95% acetonitrile and 5% water (B), was maintained at a constant flow rate (1 mL/min). For all LC-MS experiments, the column effluent was split to divert 20-25% into TSQ Quantum (ThermoElectron, San Jose, CA) mass spectrometer and the balance into a Flow Scintillation Analyzer (FSA) analyzer.

15

Mobile Phase Gradient:

Separation of metabolites was achieved using programmed linear changes in mobile phase composition as summarized in the following table:

20

Time (min)	%A	%B
0.0	90	10
10.0	70	30
40.0	30	70
40.1	10	90
50.0	10	90
50.1	90	10
60.0	90	10

HPLC and FSA System:

Equipment	Model and Vendor
HPLC Pump, Controller, Degasser, Column Oven and Autosampler	Alliance Model 2690 (Waters Corp., Milford, MA)
Flow Scintillation Analyzer (FSA)	Model 500TR (Packard Instrument Co., Meriden, CT)
Flow Scintillation Analyzer Cell Volume	250 or 500 μ L (Packard Instrument Co., Meriden, CT)
Scintillation Fluid	Ultima Flo M at 2.4 mL/min (Packard Instrument Co., Meriden, CT)
Column	Luna Phenyl-Hexyl 250 x 4.6 mm, 5- μ m particle size (Phenomenex, Torrance, CA).
Guard Column	MetaGuard Polaris C18-A, 5- μ m particle size (Metachem Technologies, Torrance, CA).

5

Mass Spectrometer:

All LC-MS and LC-MS/MS experiments were performed using a TSQ mass spectrometer (ThermoElectron, San Jose, CA) nominally operated under the conditions listed below:

Parameter	Setting
Ionization Source	Electrospray Ionization (ESI)
Ionization Mode	Positive
Spray Needle Voltage	4.0 - 4.5 kV
Capillary Temperature	250 – 270°C
Sample Flow rate	0.20 – 0.25 mL/min after splitting
Sheath Gas	Nitrogen (25 – 50)
Auxiliary Gas	Nitrogen (4 – 15)

Radiochromatograms from study samples were examined to locate radioactive peaks corresponding to metabolites. After correcting for the delay time (0.2-0.5 min), each radiolabelled peak was examined for possible molecular ions related to the drug and/or its putative metabolites. Based on the elution order, metabolite peak labels were assigned as M1 to M48 where M48 is the first eluting compound and M1 is the last to elute from the column. (see Figures 1-3 below). When available, synthetic reference standards were used to confirm the structural assignment.

10 Results

As shown in **Table 1**, following 50 mg single oral administration of VIC to healthy male volunteers, the dose was near equally eliminated in urine and feces. By contrast, a majority (53-71%) of the dose was recovered in the feces from all non-clinical species investigated. As shown in **Figure 1**, VIC was rapidly and extensively metabolized in human, monkey and rat after a single 50 mg, 6-mg/kg, and 5-mg/kg oral administration of ¹⁴C-VIC, respectively. Since there were no sex-related qualitative differences in the metabolism of VIC, only the profiles for each matrix from male rats and monkeys are shown in **Figures 2-4**.

Table 1. Excretion of radioactivity as % of dose in humans (50 mg dose), monkeys (5 mg/kg dose) and rats (6 mg/kg dose) following a single oral administration of ¹⁴C-Vicriviroc.

Time (h)	Human (n =8)		Monkey (n =4)				Rat (n =3)			
	Urine	Feces	Urine		Feces		Urine		Feces	
	M	M	M	F	M	F	M	F	M	F
Total ^b	47.1	45.1	26.3	25.8	48.6	56.4	18.0	15.6	69.1	72.9

a: Number of animals
b: Urine and fecal samples were collected for 0-336, 0-432 and 0-168 hr from humans, monkeys and rats respectively.

5 Figure 1 shows the biotransformation of Vicriviroc in Human, Monkey and Rat following a single oral dose of ¹⁴C-VIC.

Figure 2 shows a comparison of representative radiochromatographic Profiles of Pooled Plasma Extract Following a Single Oral Administration of Vicriviroc to Healthy Male Volunteers, Male Monkeys and Rats.

10 The following table describes the distribution of compound 29A (vicriviroc) and its metabolites in plasma in human, monkey and rat species.

Species	VIC and Metabolites (Plasma)		
	Major	Minor	Trace
Human	Vicriviroc (VIC)	VIC-N-Oxide (M2/M3). O-desmethyl-VIC (M15), O-desmethyl-VIC-glucuronide (M35), monoxy-O-desmethyl-VIC-glucuronide (M37) & N-desalkyl-VIC (M41)	M4 (m/z 550), M7 (m/z 538), M10 (m/z 508), M14 (m/z 550), M16 (m/z 494), M18/M19 (m/z 536), M20/M20a (m/z 534), M21/M22 (m/z 536), M25 (m/z 520), M25e/M25f/M25g (m/z 649), M30/M31 (m/z 536), M35b/M37a (534) & M36 (m/z 712)
Monkey	Vicriviroc (VIC)	VIC-N-Oxide (M2/M3). VIC-hydroxylamine (M7) O-desmethyl-VIC (M15), O-desmethyl-VIC-glucuronide (M35), VIC-hydroxylamine-glucuronide (M26), O-desmethyl-VIC-glucuronide (M35), VIC-carboxylic acid (M35b/M37a), monoxy-O-desmethyl-VIC-glucuronide (M37), N-desalkyl-VIC (M41) &	M1 (m/z 400), M4 (m/z 550), M6 (m/z 518), M16 (m/z 494), M18/M19 (m/z 536), M21/M22 (m/z 536), M25 (m/z 520), M25e/M25f/M25g (m/z 649), M28 (m/z 480) & M36 (m/z 712)

		monooxy-N-desalkyl-VIC (M45/M46/M47)	
Rat	Vicriviroc (VIC)	VIC-N-Oxide (M2/M3), monoxy-VIC (M4), O-desmethyl-VIC (M15), O-desmethyl-VIC (M25), N-desalkyl-VIC (M41) & monoxy-N-desalkyl-VIC (M45/M46/M47)	M10 (m/z 508), M14 (m/z 550), M16 (m/z 494), M18/M19 (m/z 536), M20/M20a (m/z 534), M22 (m/z 536), M27 (m/z 536), M30/M31 (m/z 536), M35 (m/z 696) & M36/M37 (m/z 712)
Major: Components with $\geq 20\%$ of the total chromatographic radioactivity (TCR);			
Minor: Components between 3 and 20% of the TCR;			
Trace: Components with $< 3\%$ of the TCR and/or only detected with a mass spectrometer			

Based on the above, the following observations can be made:

- Qualitatively similar profiles were observed in plasma from human, monkey and rat.

5

- The major circulating drug derived component in human, monkey and rat was VIC.
- While glucuronide conjugate of O-desmethyl-VIC (M35) was a prominent circulating metabolite in human and monkey plasma, in rats this metabolite was only detected in trace quantities.

10

- There was no human specific circulating metabolite detected.

Figure 3 shows a Comparison of Representative Radiochromatographic Profiles of Pooled Urine Following a Single Oral Administration of Vicriviroc to Healthy Male Volunteers, Male Monkeys and Rats.

15

The following table describes the distribution of compound 29A (vicriviroc) and its metabolites in urine of human, monkey and rat species.

species	VIC and Metabolites (Urine)		
	Major	Minor	Trace
Human	O-desmethyl-VIC-glucuronide (M35) & N-desalkyl-VIC (M41)	VIC, VIC-N-Oxide (M2/M3). O-desmethyl-VIC (M15), monooxy-O-desmethyl-VIC (M18/M19), M20/M20a (m/z 534), monooxy-O-desmethyl-VIC-glucuronide (M37) & monooxy-N-desalkyl-VIC (M45/M46/M47)	M1 (m/z 400), M4 (m/z 550), M7 (m/z 538), M10 (m/z 508), M14 (m/z 550), M16 (m/z 494), M18/M19 (m/z 536), M19a/M19b (m/z 534), M21/M22 (m/z 536), M22a/M22b (m/z 550), M25 (m/z 520), M25e/M25f/M25g (m/z 649), M28 (480), M34a/M34b/M34c (m/z 712), M30/M31 (m/z 536), M35b/M37a (534) & M36 (m/z 712)
Monkey	O-desmethyl-VIC-glucuronide (M35), N-desalkyl-VIC (M41) & monooxy-N-desalkyl-VIC (M45/M46/M47)	VIC, VIC-N-Oxide (M2/M3), VIC-hydroxylamine (M7), monooxy-O-desmethyl-VIC (M18/M19), M20/M20a (m/z 534), monooxy-O-desmethyl-VIC (M21/M22), VIC-hydroxylamine-glucuronide (M26) & monooxy-O-desmethyl-VIC-glucuronide (M37)	M1 (m/z 400), M4 (m/z 550), M6 (m/z 518), M10 (m/z 508), M15 (m/z 536), M16 (m/z 494), M23 (m/z 494), M25 (m/z 520), M25e/M25f/M25g (m/z 649), M28 (480) & M36 (m/z 712)
Rat	N-desalkyl-VIC (M41)	VIC, VIC-N-Oxide (M2/M3), O-desmethyl-VIC (M15), N, N-desalkyl-VIC (M16), monooxy-O-desmethyl-VIC (M18/M19), monooxy-O-desmethyl-VIC (M21/M22), O-desmethyl-VIC (M25), N, N-dealkyl-O-desmethyl-VIC (M28), O-desmethyl-VIC-glucuronide (M35) & monooxy-N-desalkyl-VIC (M45/M46/M47)	M1 (m/z 400), M4 (m/z 550), M6 (m/z 518), M10 (m/z 508), M20/M20a (m/z 534) & M35b/M37a (m/z 534)

Major: Components with $\geq 3\%$ of the administered dose.

Minor: Components between 0.5 and 3% of the administered dose.

Trace: Components with $< 0.5\%$ of the administered dose and/or only detected with a mass spectrometer

Based on the above, the following observations can be made:

- Major urinary metabolites N-desalkyl-VIC (M41) and O-desmethyl-VIC-glucuronide (M35) collectively accounted for 21%, 8% and 4% of the dose in human, monkey and rat, respectively.

- While M35 contributed to 11% and 3% of the dose in urine, this metabolite accounted for less than 1% in the urine from rat.

Figure 4 shows a comparison of representative radiochromatographic profiles of

5 pooled fecal extract following a single oral administration of Vicriviroc to healthy male volunteers, male monkeys and rats.

The following table describes the distribution of compound 29A (vicriviroc) and its metabolites in feces of human, monkey and rat species.

Species	VIC and Metabolites (Feces)		
	Major	Minor	Trace
Human	N-desalkyl-VIC (M41) & M20/M20a (m/z 534)	VIC, Monooxy-VIC (M14), O-desmethyl-VIC (M15), N, N-desalkyl-VIC (M16), N, N-desalkyl-VIC (M16a), monooxy-O-desmethyl-VIC (M19), M25e/M25f/M25g (m/z 649), VIC-carboxylic acid (M35b/M37a) & monooxy-N-desalkyl-VIC (M45/M46/M47)	M6 (m/z 518), M7 (m/z 538), M10 (m/z 508), M14 (m/z 550), M19a/M19b (m/z 534), M23 (m/z 494), M25 (m/z 520), M27 (m/z 536) & M28 (480)
Monkey	N-desalkyl-VIC (M41) & M20/M20a (m/z 534)	VIC, VIC-hydroxylamine (M7), N, N-desalkyl-VIC (M16a), N, N-desalkyl-VIC (M23), monooxy-VIC (M22a), M25e/M25f?M25g (m/z 649), N, N-desalkyl-O-desmethyl-VIC (M28), monooxy-VIC (M33), VIC-carboxylic acid (M35b/M37a) & monooxy-N-desalkyl-VIC (M45/M46/M47)	M1 (m/z 400), M6 (m/z 518), M10 (m/z 508), M15 (m/z 520), M16 (m/z 494) & M18/M19 (m/z 536) & M21/M22 (m/z 536)
Rat	N-desalkyl-VIC (M41) & O-desmethyl-VIC (M15)	VIC, monooxy-VIC (M4), VIC-hydroxylamine (M7), N, N-desalkyl-VIC (M16), monooxy-O-desmethyl-VIC (M19), O-desmethyl-VIC (M25), M25e/M25f/M25g (m/z 649), N, N-desalkyl-O-desmethyl-VIC (M28), M35a1 (m/z 600), VIC-carboxylic acid (M35b/M37a) & monooxy-N-desalkyl-VIC (M45/M46/M47)	M1 (m/z 400), M2/M3 (m/z 550), M5a/M5b (m/z 548), M6 (m/z 518), M10 (m/z 508), M20/M20a (m/z 534) & M25d (m/z 536)

Major: Components with $\geq 5\%$ of the administered dose.

Minor: Components between 1 and 5% of the administered dose.

Trace: Components with $< 1\%$ of the administered dose and/or only detected with a mass spectrometer

Based on the above, the following observation can be made:

- Major fecal metabolites which collectively accounted for 16-35% of the administered dose in human, monkey and rat included N-desalkyl-VIC (M41), O-demethyl-VIC(M15) and a oxidative product of M15 (M20/M20a at m/z of 534).


5

The overall conclusion from the metabolite studies are as follows:


- Following a single oral 50 mg administration to healthy volunteers, Vicriviroc (VIC, compound 29A) and its metabolites were near equally excreted in feces and urine. By contrast, following a single 5 mg/kg and 6 mg/kg oral administration of VIC to rats and monkeys, respectively, radioactivity was predominantly eliminated in the feces.
- In all species investigated, the primary biotransformation of VIC involved O-demethylation, N-dealkylation, oxidation and glucuronidation.

No human specific metabolites were observed following a single 50 mg oral administration of VIC to healthy male volunteers.

Example 30




20 Step 1:




A solution of *p*-trifluoromethoxy benzaldehyde (0.48 ml, 3.36 mmol), the piperidino-pipiperazine (1.00g, 3.36 mmol) and benzotriazole (0.48g, 4.00 mmol) in dry toluene were heated at reflux for 6 h. The reaction mixture was cooled to 25 RT and the solvent was removed *in vacuo*. Following NMR verification of the formation of the product, the product was used without further purification in the next step.

100

Step 2:





To a solution of the product of Step 1 (1.16g, 1.97 mmol) in 20 ml of toluene was added a solution of *n*-propyl magnesium bromide (2M in Et₂O, 1.1 ml) and the mixture stirred at RT for 15 h. The reaction mixture was quenched by pouring onto ice and saturated aqueous NH₄Cl solution. The aqueous layer was extracted with EtOAc, washed with 1M NaOH solution, water and brine. Concentration and purification by FSGC (20% EtOAc - hexane) provided the desired product **A**. Further elution with 30% EtOAc in hexane gave the (R, S) diastereomer **B**.

Step 3: The amine **A** was treated with TFA in CH₂Cl₂ to remove the BOC-protecting group. Coupling of the free piperidine with acids using EDCI / HOBT provided compounds 30-30B in the following table; similar methods were used to prepare compounds 30C-I.




15

Ex.	R ^{8a}	R ³	R ²	Mp (°C)	HRMS (MH ⁺ found)
30	-OCF ₃	n-Pr		237	546.3314
30A	-OCF ₃	n-Pr		241	548.3217
30B	-OCF ₃	n-Pr		219	632.3779
30C	H			175-178	--
30D	H			177-189	--
30E	H			84-90	--

30F	-CF ₃	-  CF ₃		180-192	--
30G [*]	-CF ₃	- 		180-186	--
30H	H	- 		178-188	--
30I [*]	-OCF ₃	- 		165-175	--

^{*}Mixture of diastereomers

Example 31



5 A solution of the product of Example 12, step 2 (150 mg, 0.27 mmol), imidazole (27.4 mg, 0.403 mmol), 1,10-phenanthroline (48 mg, 0.27 mmol), *trans,trans*-dibenzylideneacetone (6.28 mg, 0.027 mmol), copper (II) trifluoromethanesulfonate benzene complex (15 mg, 0.027 mmol) and Cs₂CO₃ (96.1 mg, 0.30 mmol) in xylene (2 ml) was stirred at 110° C for 5 days. The reaction mixture was cooled to RT and saturated NaHCO₃ was added. Extractive EtOAc work up followed by silica gel chromatography gave the title compound (70 mg, 52% yield). Dec. 215° C (HCl salt). HRMS calcd for C₂₉H₃₉CIN₃OS (M+H⁺) 500.3389, found 500.3396.

10 15 The following assays can be used to determine the CCR5 antagonistic activity of the compounds of the disclosure.

CCR5 Membrane Binding Assay:

20 A high throughput screen utilizing a CCR5 membrane binding assay identifies inhibitors of RANTES binding. This assay utilizes membranes prepared from NIH 3T3 cells expressing the human CCR5 chemokine receptor which have the ability to bind to RANTES, a natural ligand for the receptor. Using a 96-well plate format, membrane preparations are incubated with ¹²⁵I-RANTES in the presence or absence of compound for one hour. Compounds are serially diluted over a wide range of 0.001ug/ml to 1 ug/ml and tested in triplicates. Reaction cocktails are harvested 25 through glass fiber filters, and washed thoroughly. Total counts for replicates are averaged and data reported as the concentration required to inhibit 50 percent of

total ^{125}I -RANTES binding. Compounds with potent activity in the membrane binding assay are further characterized in secondary cell-based HIV-1 entry and replication assays.

HIV-1 Entry Assay:

5 Replication defective HIV-1 reporter virions are generated by cotransfection of a plasmid encoding the NL4-3 strain of HIV-1 (which has been modified by mutation of the envelope gene and introduction of a luciferase reporter plasmid) along with a plasmid encoding one of several HIV-1 envelope genes as described by Connor et al , *Virology*, 206 (1995), p. 935-944. Following transfection of the two plasmids by
10 calcium phosphate precipitation, the viral supernatants are harvested on day 3 and a functional viral titer determined. These stocks are then used to infect U87 cells stably expressing CD4 and the chemokine receptor CCR5 which have been preincubated with or without test compound. Infections are carried out for 2 hours at 37 °C, the cells washed and media replaced with fresh media containing compound.
15 The cells are incubated for 3 days, lysed and luciferase activity determined. Results are reported as the concentration of compound required to inhibit 50% of the luciferase activity in the control cultures.

HIV-1 Replication Assay:

20 This assay uses primary peripheral blood mononuclear cells or the stable U87-CCR5 cell line to determine the effect of anti-CCR5 compounds to block infection of primary HIV-1 strains. The primary lymphocytes are purified from normal healthy donors and stimulated *in vitro* with PHA and IL-2 three days prior to infection. Using a 96-well plate format, cells are pretreated with drug for 1 hour at 37 °C and subsequently infected with an M-tropic HIV-1 isolates. Following infection,
25 the cells are washed to remove residual inoculum and cultured in the presence of compound for 4 days. Culture supernatants are harvested and viral replication measured by determination of viral p24 antigen concentration.

Calcium Flux Assay:

30 Cells expressing the HIV coreceptor CCR5 are loaded with calcium sensitive dyes prior to addition of compound or the natural CCR5 ligand. Compounds with agonist properties will induce a calcium flux signal in the cell, while CCR5 antagonists are identified as compounds which do not induce signaling by themselves but are capable of blocking signaling by the natural ligand RANTES.

GTP γ S Binding Assay:

35 A GTP γ S binding assay measures receptor activation by CCR5 ligands. This assay measures the binding of ^{35}S labeled-GTP to receptor coupled G-proteins that occurs as a result of receptor activation by an appropriate ligand. In this assay, the CCR5 ligand, RANTES, is incubated with membranes from CCR5 expressing cells

and binding to the receptor activation (or binding) is determined by assaying for bound ³⁵S label. The assay quantitatively determines if compounds exhibit agonist characteristics by inducing activation of the receptor or alternatively antagonist properties by measuring inhibition of RANTES binding in a competitive or non-competitive fashion.

5 Chemotaxis Assay:

The chemotaxis assay is a functional assay which characterizes the agonist vs. antagonist properties of the test compounds. The assay measures the ability of a non-adherent murine cell line expressing human CCR5 (BaF-550) to migrate across a membrane in response to either test compounds or natural ligands (i.e., RANTES, MIP-1 β). Cells migrate across the permeable membrane towards compounds with agonist activity. Compounds that are antagonists not only fail to induce chemotaxis, but are also capable of inhibiting cell migration in response to known CCR5 ligands.

The role of CC chemokine receptors such as CCR-5 receptors in inflammatory conditions has been reported in such publications as Immunology Letters, 57, (1997), 117-120 (arthritis); Clinical & Experimental Rheumatology, 17 (4) (1999), p. 419-425 (rheumatoid arthritis); Clinical & Experimental Immunology, 117 (2) (1999), p.237-243 (atopic dermatitis); International Journal of Immunopharmacology, 20 (11) (1998), p. 661-7 (psoriasis); Journal of Allergy & Clinical Immunology, 100 (6, Pt 2) (1997), p. 20 S52-5 (asthma); and Journal of Immunology, 159 (6) (1997), p. 2962-72 (allergies).

In the assay to determine inhibition of RANTES binding, compounds disclosed herein range in activity from a Ki of about 0.5 to about 1500 nM, with preferred compounds having a range of activity from about 0.5 to about 750 nM, more preferably about 0.5 to 300 nM, and most preferably about 0.5 to 50 nM. The results for preferred and representative compounds of formulas I and II in the test to determine inhibition of RANTES binding are given in the table below. In the table, "Ex. No." stands for "Example Number" and "nM" stands for "nanomolar."

Ex. No.	Ki (nM) Inhibition of RANTES binding
3C	9.97
6C	30.0
6E	1.43
11	10.5
16	60

20A	1300
23	2.95

For preparing pharmaceutical compositions of the CCR5 antagonist compounds described by this disclosure, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g. magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

Liquid form preparations include solutions, suspensions and emulsions. As an example may be mentioned water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions for intranasal administration.

Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, e.g. nitrogen.

Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

The CCR5 antagonist compounds of the disclosure may also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

Preferably the CCR5 antagonist compound is administered orally.

Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, e.g., an effective amount to achieve the desired purpose.

5 The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 10 mg to about 500 mg, preferably from about 25 mg to about 300 mg, more preferably from about 50 mg to about 250 mg, and most preferably from about 55 mg to about 200 mg, according to the particular application.

10 The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

15 The amount and frequency of administration of the CCR5 antagonist compounds of the disclosure and/or the pharmaceutically acceptable salts thereof will be regulated according to the judgment of the attending clinician considering such factors as age, condition and size of the patient as well as severity of the symptoms being treated. A typical recommended daily dosage 20 regimen for oral administration can range from about 100 mg/day to about 300 mg/day, preferably 150 mg/day to 250 mg/day, more preferably about 200 mg/day, in two to four divided doses.

25 The doses and dosage regimen of the NRTIs, NNRTIs, PIs and other agents will be determined by attending clinician in view of the approved doses and dosage regimen in the package insert or as set forth in the protocol taking into consideration the age, sex and condition of the patient and the severity of the HIV-1 infection.

30 While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

35 In the claims which follow and in the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as


- 105a -

"comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.

5 It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound in pure and isolated form, said compound is:



5

or a pharmaceutically acceptable salt or solvate thereof.

10 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof in combination with a pharmaceutically acceptable carrier.

15 3. A method of treating Human Immunodeficiency Virus comprising administering to a human in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

20 4. The method of claim 3 further comprising administering one or more antiviral or other agents useful in the treatment of Human Immuno-deficiency Virus in combination with the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

25 5. The method of claim 4 wherein the antiviral agent is selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

30 6. The method of claim 5 wherein the antiviral agent is selected from the group consisting of zidovudine, lamivudine, zalcitabine, didanosine, stavudine, abacavir, adefovir dipivoxil, lobucavir, BCH-10652, emtricitabine, beta-L-FD4, DAPD, iodenosine, nevirapine, delavirdine, efavirenz, PNU-142721, AG-1549, MKC-442, (+)-calanolide A and B, saquinavir, indinavir, ritonavir, nelfinavir, lopinavir, DMP-450, BMS-2322623, ABT-378, amprenavir, hydroxyurea, ribavirin, IL-2, IL-12, penta fuside, Yissum No. 11607 and AG-1549.

7. A method treating solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, comprising administering to a human in need of such treatment a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof.

5

8. The method of claim 7 for the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis, further comprising one or more other agents useful in the treatment of said diseases.


10

9. A kit comprising in separate containers in a single package pharmaceutical compositions for use in combination to treat Human Immunodeficiency Virus which comprises in one container a pharmaceutical composition comprising an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof in a pharmaceutically acceptable carrier, and in separate containers, one or more pharmaceutical composition comprising an effective amount of a antiviral or other agent useful in the treatment of Human Immunodeficiency Virus in a pharmaceutically acceptable carrier.

15

20

10. A method of determining if a patient has been administered the compound of the formula



25


the method comprising the step of determining if a plasma, urine, bile or fecal sample obtained from the patient shows the presence of a compound of claim 1.

30

11. Use of a compound of claim 1 or a pharmaceutically acceptable salt or solvate thereof for the preparation of a medicament for the treatment of Human Immunodeficiency Virus.

12. Use of a compound of claim 1 or a pharmaceutically acceptable salt, solvate or ester thereof for the preparation of a medicament for the treatment of solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis psoriasis, asthma, allergies or multiple sclerosis.
- 5
13. The compound of claim 1, the composition of claim 2, the method of any one of claims 3, 7 and 10, the kit of claim 9 or the use of claim 11 or 12 substantially as herein described with reference to any one of the Examples.
- 10

Figure 1



(H, M, R) : (Observed in Human, Monkey and Rat)


Figure 2


Figure 3

Figure 4

5

